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ABSTRACT
BIOLOGICALLY INTERPRETABLE, INTEGRATIVE DEEP LEARNING FOR
CANCER SURVIVAL ANALYSIS
Jie Hao, Ph.D.
Kennesaw State University, 2019
Supervising Professor: Mingon Kang
Identifying complex biological processes associated to patients’ survival time
at the cellular and molecular level is critical not only for developing new treatments
for patients but also for accurate survival prediction. However, highly nonlinear and
high-dimension, low-sample size (HDLSS) data cause computational challenges in
survival analysis. We developed a novel family of pathway-based, sparse deep neural
networks (PASNet) for cancer survival analysis. PASNet family is a biologically in-
terpretable neural network model where nodes in the network correspond to specific
genes and pathways, while capturing nonlinear and hierarchical effects of biologi-
cal pathways associated with certain clinical outcomes. Furthermore, integration of
heterogeneous types of biological data from biospecimen holds promise of improving
survival prediction and personalized therapies in cancer. Specifically, the integration
of genomic data and histopathological images enhances survival predictions and per-
sonalized treatments in cancer study, while providing an in-depth understanding of
genetic mechanisms and phenotypic patterns of cancer. Two proposed models will
be introduced for integrating multi-omics data and pathological images, respectively.
Each model in PASNet family was evaluated by comparing the performance of cur-
rent cutting-edge models with The Cancer Genome Atlas (TCGA) cancer data. In
v
the extensive experiments, PASNet family outperformed the benchmarking methods,
and the outstanding performance was statistically assessed. More importantly, PAS-
Net family showed the capability to interpret a multi-layered biological system. A
number of biological literature in GBM supported the biological interpretation of the
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that corresponds with clinical outcomes, e.g. a binary class that has
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domly selected using a dropout technique and trained. (c) Sparse coding
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pathway layer in PASNet. (a) The weights between the hidden layer and
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LTS/non-LTS samples. The vertical dotted lines indicates LTS/non-
LTS samples are significantly distinguished by top 16 pathways. (c)
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1.6 Graphical representation of the 10 top-ranked pathways by PASNet. (a)
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CHAPTER 1
PATHWAY-ASSOCIATED SPARSE DEEP NEURAL NETWORK FOR
PROGNOSIS PREDICTION FROM HIGH-THROUGHPUT DATA
1.1 Background
Predicting prognosis in patients from large-scale genomic data is a fundamen-
tally challenging problem in genomic medicine [1, 2, 3]. Along with the rapid advances
of high-throughput technologies and their effectivenesses, high-dimensional genomic
data provides more accurate and richer biological descriptions of clinical phenotypes
of interests than ever before. Therefore, translating large-scale genomic profiles to
clinical outcomes not only improves predicting patient prognosis but also helps in
identifying prognostic factors and biological processes.
The capabilities of high-level biological representation and interpretation of the
prognosis are often more desired in biomedical research rather than merely improv-
ing predictive performance. Pathway-based analysis is an approach that a number of
studies have been investigating to improve both predictive performance and biological
interpretability [4, 5, 6]. In pathway-based analyses, the incorporation of biological
pathway databases in a model takes advantage of leveraging prior biological knowl-
edge so that potential prognostic factors of well-known biological functionality can
be identified. Pathway-based analyses identify biological links between pathways and
clinical outcomes and enable the interpretation of biological processes where their cor-
responding genes and proteins are involved. Thus, pathway-based interpretation and
visualization provide an intuitive and comprehensive understanding of functionally-
related molecular mechanisms.
Moreover, pathway-based approaches have shown more reproducible analysis
results than gene expression data analysis alone [4, 7, 8, 9, 10]. High-level represen-
tations of gene co-expressions are considered in most pathway-based analyses; each
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of which represents a biological pathway while preserving the original information.
Thus, pathway-based analyses remedy the limitations of gene expression data, which
are intrinsically sensitive to stochastic fluctuations and are often caused by multiple
potential sources, such as inherent stochasticity of biochemical processes, environ-
mental differences, and genetic mutation [11]. Pathway-based markers were proposed
for classifying breast cancer metastasis and ovarian cancer survival time [5]. Cancer
subtypes were discovered with pathway-based markers via Restricted Boltzmann Ma-
chine (RBM) [8]. A group LASSO-based approach associated genes with pathways
and characterized them based on biological pathways [10]. Higher-order functional
representation of pathway-based metabolic features provided reproducible biomarkers
for breast cancer diagnosis [9].
However, reliable and accurate prognosis still remains poor in many diseases
due to the following challenges: high-dimension, low-sample size data and complex
nonlinear effects between biological components.
Genomic data are highly dimensional relative to their sample sizes. High-
dimension, low-sample size (HDLSS) data often make prediction models sensitive
to noise and false positive associations, which consequently make predicting accurate
prognoses difficult. LASSO-based approaches have been mainly considered to esti-
mate the effects of a gene set that are associated with various types of clinical out-
comes on HDLSS data. The LASSO-based approaches embed sparse coding schemes
into linear or logistic regression models for selecting few but greatly informative fea-
tures among the high-dimensional data. For instance, a logistic regression with sparse
regularization was applied for the prognostic model of mortality after acute myocar-
dial infarction [12]. Random LASSO was proposed to enhance the LASSO solution by
applying multiple bootstrapping and was applied to predict patients’ survival times
with glioblastoma gene expression data [13]. LASSO-based regression models as a
prediction model were validated with multiple imputed data in chronic obstructive
pulmonary disease patients [14].
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Pathway-based analysis also helps to reduce data dimensionality. The number of
biological pathways is relatively smaller than the number of genes, and a set of genes
in the same pathway can be represented by the pathway’s effect. Thus, pathways
can be used as summary variables for the input of the predictive model instead of
including all genes, which consequently reduces the model complexity.
Most association studies between a gene set and various clinical outcomes have
considered linear or logistic regression models for identifying prognostic factors as well
as understanding a biological mechanism of the progression of disease. However, non-
linear effects of genes or pathways may fail to be identified by linear-based approaches.
As a solution, kernel-based models have been proposed to capture nonlinear effects
of complex pathways [15, 16]. Multiple kernel learning models were introduced to
aggregate complex effects from multiple pathways [17, 18]. Kernel Principle Compo-
nent Analysis (KPCA) was applied to reduce the dimensionality of the feature space
by using the correlation structure of the pathways [18].
Recently, several attempts to capture hierarchical effects of genes and pathways
have been made. Inferences of multilayered hierarchical gene regulatory networks have
been considered to understand how pathways regulate each other hierarchically. A
bottom-up graphic Gaussian model [19] and a recursive random forest algorithm [20]
were proposed to construct multilayered hierarchical gene regulatory networks. More-
over, complex biological networks were modeled by inferring the multiple hierarchical
models (1) between gene expression and pathways and (2) within pathways [21]. How-
ever, complex hierarchical relationships between pathways have not been considered
for prognostic studies yet, to the best of our knowledge, although hierarchical effects
of pathways are prevalent in biological systems [22].
In this chapter, we propose a Pathway-Associated Sparse Deep Neural Network
(PASNet) to achieve the goals:
• to predict prognosis in patients accurately by incorporating biological pathways,
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• to provide a solution for hierarchical interpretation of nonlinear relationships
between biological pathways of disease systematically, and
• to handle with computational problems, such as HDLSS data.
An innovative aspect of our model is biological interpretability; we achieved this with
sparse coding and by constructing hidden layers with biological pathways, which op-
pose the black box nature of deep learning. Our new sparse deep learning architecture
represents multiple molecular biological layers, such as a gene layer and a pathway
layer, along with their hierarchical relationships, which use sparse regularization.
1.2 Related Works in Deep Learning
In recent years, deep learning has been spotlighted as the most active research
field in various machine learning communities, such as image analysis, speech recogni-
tion, and natural language processing as its promising potential is being actively dis-
cussed in bioinformatics and biomedicine [23]. Most deep learning-based approaches
have been developed for classification and association studies in bioinformatics. For
instance, D-GEX infers the expression of target genes from landmark genes, captur-
ing the nonlinear relationships by combining gene expression, DNA methylation, and
miRNA expression data [24]. A convolutional neural network (CNN) was adapted
to predict DNA-protein binding sites with Chromatin Immunoprecipitation sequenc-
ing (ChIP-seq) data [25]. Additionally, CNN-based DeepBind was proposed to pre-
dict whether a specific DNA/RNA binding protein will bind to a specific DNA se-
quence [26]. The functionality of non-coding variants was predicted by DeepSEA by
employing a CNN model [27].
Although only a small subset of deep learning research has been reported in
bioinformatics due to the difficulty of structure definition and interpretation, the fu-
ture of deep learning in biology and medicine is promising [28]. First, since a neural
network is inspired by the neurons in the human brain, a neuron network architecture
is applicable to modeling a mechanism for a complex biological system. Specifically,
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deep learning approaches take advantage of flexible representation of hierarchical
structures from inputs to outputs. The representation of nonlinear effects of neurons
in multiple layers in neural networks may be able to model hierarchical biological
signals. DCell constructs a multi-layer neural network based on extensive prior bio-
logical knowledge to simulate the growth of a eukaryotic cell [29]. However, DCell’s
network architecture is entirely based on well-known prior biological knowledge, so
the model was applied to relatively simple biological system of yeast. Moreover, deep
learning captures nonlinear effects of variables with high-level feature representation,
which allows deep learning to outperform other state-of-the-art methods.
However, training deep neural networks with HDLSS data poses a computa-
tional problem. A large number of parameters are involved in deep neural networks,
and it often makes the training infeasible or causes a model overfit on HDLSS data.
Particularly, backpropagation gradients in neural networks are of high variance on
HDLSS data, which consequently causes the model overfit [30]. In order to tackle
the HDLSS problem, the leave-one-out approach was used to avoid the overfitting
problem in backpropagation [31]. Regarding backpropagation, the risk of overfitting
was examined with validation data by the leave-one-out approach and terminates
the training early when overfitting occurs. For an alternative solution, an attempt to
reduce the dimensionality of the input space to a feasible size has been made [32]. Di-
mension reduction techniques, such as subsampled randomized Hadamard transform
(SRHT) and Count Sketch-base construction, were utilized to reduce the dimensional
size of the input data. Then, the projected data into the lower space were introduced
to a neural network for training.
For HDLSS data, feature selection is one of the conventional approaches. Deep
Feature Selection (DFS) was developed to select a discriminative feature subset in a
deep learning model [33]. Although DFS is not the optimal solution to low-sample
size data, DFS shows that deep learning can detect informative and discriminative
features of nonlinearity effects through multiple layers with high-dimensional data.
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Then, Deep Neural Pursuit (DNP) improved the solution of the feature selection in
deep learning, taking the HDLSS data problem into account [30]. DNP iteratively
augments features in the input layer by performing multiple dropouts. The multiple
dropouts grant the ability to train a small-sized sub-network at a time and to compute
gradients with low variance for alleviating the overfitting problem.
1.3 Methods
Pathway-Associated Sparse Deep Neural Network (PASNet) identifies a subset
of genes and pathways involved in a disease as prognostic biomarkers, as well as their
interactions. PASNet models a multilayered, hierarchical biological system of genes
and pathways on a disease, while leveraging the strengths of deep learning for com-
petitive predictive performance. The sparsity of PASNet allows one to interpret the
model, which is what conventional fully-connected networks lack. The architecture of
PASNet and the strategies for training a sparse neural network model with HDLSS
and imbalanced data are described.
1.3.1 The Architecture of PASNet
PASNet incorporates biological pathways and the concept of sparse modeling
based on Deep Neural Network (DNN). The neural network architecture of PASNet
consists of a gene layer (an input layer), a pathway layer that represents the bio-
logical pathways linked with input genes, a hidden layer that represents hierarchical
relationships among biological pathways, and an output layer that corresponds with
clinical outcomes, e.g. binary classes of long-term and short-term survival, stages of
cancer (see Figure 1.1).
In PASNet, sparse coding is considered on the connections between layers for
model interpretability. Sparse coding provides a solution to capture significant com-













Figure 1.1: Architecture of PASNet. The structure of PASNet is constructed by a gene
layer (an input layer), a pathway layer that represents the biological pathways linked
with input genes, a hidden layer that represents hierarchical relationships among
biological pathways, and an output layer that corresponds with clinical outcomes,
e.g. a binary class that has long-term survival and short-term survival, stages of
cancer.
only a few biological components. On the other hand, conventional fully-connected
networks lack to represent biological mechanisms.
Gene Layer
The gene layer (as an input layer) corresponds to gene expression data. A
patient sample of m gene expressions is formed as a column vector, which is denoted
by x = {x1, x2, ..., xm}. Each input node represents one gene.
Pathway Layer
The pathway layer represents biological pathways, where each node indicates
an individual pathway. The connections between the gene layer and the pathway
layer are established by well-known pathway databases (e.g., Reactome and KEGG).
Pathway databases contain associations between pathways and genes; each of which
7
provides a set of gene components. Therefore, the pathway layer makes it possible to
interpret the model as a pathway-based analysis.
To begin with initializing the connections between the gene layer and the path-
way layer, we consider a binary bi-adjacency matrix (A) from biological pathway
databases. The bi-adjacency matrix can be defined as A ∈ Bn×m, where n is number
of pathways and m is number of genes. Then, an element of A, i.e., aij, is set to one
if gene j belongs to pathway i; otherwise, zero. Sparse coding is applied based on the
matrix A to represent the relationships between genes and pathways in the model.
1.3.1.1 Hidden Layer
Biological components may cooperate with others instead of functioning alone.
A biological system involves multiple pathways which have interactions together,
whereas a node in the pathway layer indicates a biological pathway. The associative
interactions between pathways can be represented in the hidden layer. In PASNet,
the hidden layer represents biological nonlinear associations between the pathways to
outputs.
Sparse coding between the pathway and the hidden layers enables one to in-
terpret these relationships. Although we consider only a single hidden layer in this
study for simplicity’s sake, multiple hidden layers can be used for deeper hierarchical
representations of pathways. For example, if there are two hidden layers, the second
hidden layer will represent deeper hierarchical associations of the nodes of the first
hidden layer, which are association effects of pathways.
1.3.1.2 Output Layer
The output layer shows clinical outcomes for which nodes compute the posterior
probabilities. In this layer, sparse coding allows to distinguish hierarchical groups of
pathways (which are detected from hidden layers) to predict clinical outcomes. In
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PASNet, more than two clinical outcomes can be easily represented with multiple
nodes in the output layer.
Consequently, PASNet can dissect biological processes of hierarchical nonlinear
relationships and associations of genes and pathways to predict clinical outcomes.
This generative model-based approach would be useful to predict prognosis accurately
with complex HDLSS data. Furthermore, the integration of the biological structures
and prior knowledge to the model would produce a robust solution.
1.3.2 Overall Description of PASNet Training
The main challenge in training PASNet is to reduce both risk of overfitting and
computational complexity of training on HDLSS data. The related works that have
handled the HDLSS data problem are discussed in Section Related Work in Deep
Learning. To unravel the problems, PASNet optimizes a small sub-network, which
involves feasible nodes and parameters to train instead of the whole network and
then makes the sub-network sparse. Figure 1.2 illustrates the overall training flow of
PASNet.
First, we initialize the connections between the gene layer and the pathway
layer with prior biological knowledge of pathways (see Figure 1.2(a)). Active/inactive
connections are determined by the bi-adjacency matrix, A. The weights of active con-
nections and biases are randomly initialized from standard normal distribution, while
the weights of inactive connections are set to zero. The sparsity of the connections
between the gene layer and the pathway layer is invariant over the entire training.
The remaining layers are fully interconnected as the initial.
In the training phase, we repeat training sub-networks and applying sparse cod-
ing on the sub-networks until convergence (Figure 1.2(b) – (c)). A sub-network is
selected by a dropout technique, where neurons are randomly dropped in the inter-
mediate layers. In Figure 1.2(b), a small sub-network is shown with bold solid circles
and lines. Then, the small sub-network is trained by feed-forward and backpropaga-
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tion. Note that only weights and biases of the sub-network are trained. Upon the
completion of the sub-network’s training, sparse coding is applied to the sub-network
by trimming the connections that do not contribute to minimize the loss. In Fig-
ure 1.2(c), the dropped connections and nodes are marked as bold, dashed lines. The
details of the training are elucidated in the following sections.
1.3.3 Sparse Coding
Once the small sub-network is trained with the HDLSS data, the sub-network
is imposed to be sparse for the model interpretation. The sparsity of the sub-network
is determined by the mask matrix M on each layer as:
h(`+1) = a
(
(W(`) ?M(`))h(`) + b(`)
)
, (1.1)
where ? denotes element-wise multiplication, and a(·) is an activation function. h(`)
denotes an output vector on the `-th layer, and W(`) and b(`) are a weight matrix
and a bias vector, respectively. An element value of M is either one or zero, which
determines whether the associated weights are dropped in the current epoch.
The mask matrix M is generated with respect to a sparsity level (S) that
indicates the proportion of weights to be dropped in a single layer. S is a value
between 0 to 100 (e.g. [0, 10, ..., 100)), where zero creates a fully-connected layer while
100 causes no connection. The optimal S∗ is approximated on each layer individually
in the sub-network, while most related methods consider a single hyper-parameter for
the sparsity of all layers [34, 35]. The individual setting of the sparsity on each layer
shows different levels of biological associations on the genes and pathways.
We obtain the optimal sparsity level S∗ that minimizes the cost score. For
efficient computation, the cost scores are computed with a small number of finite
sparsity levels. Then, the optimal sparsity level is estimated by applying a cubic-
spline interpolation to the cost scores with the assumption that the cost function,
with respect to the sparsity level, is continuous.
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In particular, an element of M is set to one if the absolute value of the corre-
sponding weight is greater than threshold Q; otherwise, the element is zero, where Q
is an S-th percentile of absolute values of W. Note that the mask between the gene
layer and the pathway layer, i.e. M(0), is determined by the bi-adjacency matrix A
of biological pathways. Thus, the mask matrices are formulated as
M(`) =
1(|W
(`)| ≥ Q(`)), if ` 6= 0
A, if ` = 0
(1.2)
where Q(`) is the S-th percentile of |W(`)| if ` 6= 0.
1.3.4 Cost-sensitive Learning for Imbalanced Data
We refine the cost function and the backpropagation for cost-sensitive learning,
since imbalanced data causes bias of the predictions towards the majority class. We
adapt the Mean False Error (MFE) method [36], which penalizes the errors of the
majority class.
Let K be the number of clinical outcomes. The normalized cost is computed














where Ck denotes mean error on the class k, and nk is the number of samples in
the class k. yi is a vectorized ground truth class label of the i-th sample, and ỹi is
its vectorized prediction. c(·) denotes a cost function (e.g., cross-entropy loss), and
L is the total cost. ‖W‖2 denotes a L2-norm of W, and λ > 0 is a regularization
hyperparameter.
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In the backpropagation phrase, the gradient is also computed separately for
each class. Hence, the weights and biases on the `-th layer are updated by:












where η is a learning rate. The algorithm of PASNet is briefly described in Algo-
rithm 1.
Algorithm 1 Training of PASNet
1: Initialize weights W(`) and biases b(`)
2: W(0) ←W(0) ?M(0)
3: repeat
4: Select a small sub-network via dropout
5: Train the sub-network by Eq. (1.5) and Eq. (1.6)
6: Sparse coding with the optimal M(`) by Eq. (1.2)
7: W(`) ←W(`) ?M(`)
8: until convergence
1.4 Results
We conducted experiments to evaluate PASNet’s predictive performance for
long-term survival prediction in Glioblastoma multiforme (GBM). The capability of
the prediction was assessed by comparing our model with the classifiers that have been
used for long-term survival prediction. Furthermore, we will describe how PASNet
can represent the biological system of GBM in the following sections.
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1.4.1 Data
GBM is a primary brain cancer that shows poor prognosis performance. Com-
prising more than half of all brain tumors, GBM is the most prevailing and ag-
gressive malignant type of primary astrocytomas [37]. Patients with GBM have a
median survival time of approximately 15 months with intensive treatments [38].
Furthermore, long-term survival patients with GBM are rare as more than 90% of
patients are deceased within three years of diagnosis. Although treatments in neu-
rosurgery, chemotherapy, and radiotherapy have improved, the prognosis of GBM
remains poor [39]. Hence, the advancement in understanding molecular mechanisms
and related biological pathways of GBM is significant to accelerating the progress for
new treatments [38].
We used the gene expression data of GBM patients, which is available at The
Cancer Genome Atlas (TCGA, http://cancergenome.nih.gov). The dataset in-
cludes the gene expression data of 522 samples and 12,042 genes and provides survival
time and status. We considered patients who survived past 24 months (regardless of
survival status) as long-term survivals (LTS) and patients that deceased in less than
24 months as short-term survivals (non-LTS). Living patients with a survival time of
less than 24 months were excluded in the experiments and considered censored data.
Finally, we obtained 99 LTS and 376 non-LTS samples, where around 20% of the
samples were LTS patients.
For pathway-based analysis, we utilized a biological pathway database from the
Molecular Signatures Database (MSigDB) [40, 41, 42]. In MSigDB, we extracted the
biological pathways of Reactome. Then, we excluded the pathways that include less
than ten genes, because small pathways are often redundant with larger pathways [43].
As the input features, we considered the genes that belong to at least one pathway,
since pathway annotations of genes are essential to construct the mask matrix M
between the gene layer and the pathway layer. Finally, we considered 574 pathways
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and 4,359 genes in the experiments. The gene expression data were standardized to
a mean of zero and a standard deviation of one.
1.4.2 Experimental Design
We followed a typical design of conventional deep neural networks for PAS-
Net. A sigmoid function and cross-entropy were considered for the activation and
the cost function, respectively. A softmax function was used in the output layer
so that the probabilities of output nodes add up to one. For the optimal tuning
of PASNet’s training, we empirically determined the hyper-parameters by random
search before cross-validation experiments. The learning rate (η) was set to 1e−4,
and L2 regularization (λ) was set to 3e−4. Adaptive Moment Estimation (Adam)
was performed as the stochastic optimizer [44]. The dropouts for two intermedi-
ate layers were also applied with a dropping probability of 0.8 and 0.7, respec-
tively. PASNet was implemented by PyTorch, and the source code is available at
https://github.com/DataX-JieHao/PASNet.
1.4.3 Comparison
We evaluated PASNet by comparing the performance with classifiers that have
been used for prognosis prediction: Support Vector Machine (SVM), Random LASSO [13],
LASSO Logistic Regression (LLR) [1], and neural network with dropout (Dropout
NN).
Specifically, we used a SVM with a radial basis function (RBF) kernel (γ = 2−16
and C = 23.9 by two-step grid search [45]). Random LASSO was trained so that every
feature could be selected 20 times on average by bootstrapping, and the L1 regular-
ization parameter was determined by 10-fold cross-validation. The LASSO parameter
for LLR was also selected by 10-fold cross-validation. The fully-connected Dropout
NN was designed with the same numbers of intermediate layers and neurons as the
proposed PASNet as well as the dropout probabilities. The learning rate was 0.01
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and the L2 regularization was 0.005. Note that PASNet has less number of weights
to be trained in each epoch because of sparse coding, compared to Dropout NN.
Hence, the optimal hyper-parameters of L2 regularization and learning rate should
be different between PASNet and Dropout NN. We empirically searched the optimal
hyper-parameters for PASNet and Dropout NN separately through multiple experi-
ments. Dropout NN was implemented by PyTorch (https://pytorch.org/).
The experiments were carried out by stratified 5-fold cross-validation for main-
taining the same proportions of the imbalanced samples in the classes. The cross-
validation experiments were repeated ten times for performance reproducibility. Data
preprocessing, such as data normalization, was separately applied on each fold. The
testing data on each fold was scaled with the mean and standard deviation of the
training data of the same fold.
The predictive performances of the five models were evaluated with two metrics:
Area Under the Curve (AUC) and F1-scores. The Receiver Operating Characteristic
(ROC) curve (see Figure 1.3) was traced over the thresholds of scores to examine the
trade-off between True Positive Rate (TPR = TP/(TP + FN)) and False Positive
Rate (FPR = FP/(FP + TN)), where LTS was considered positive. An AUC was
computed by the area under the ROC curve. An F1-score, an average of Positive
Predicted Value (PPV = TP/(TP + FP )) and TPR, is calculated by 2(PPV ×
TPR)/(PPV + TPR). The F1-score was computed for the LTS class.
The average AUC and the average F1-score of the five methods on the test
datasets are shown in Table 1.1. PASNet outperformed others as both AUC and
F1-score are relatively high. PASNet produced AUC of 0.6622±0.013 (mean±std)
and F1-score of 0.3978±0.016. Following PASNet, Dropout NN produced AUC of
0.6408±0.014, and SVM produced AUC of 0.6337±0.015.
To statistically assess the performance of PASNet (AUC) as compared to others,
we conducted the Wilcoxon signed-rank test: a non-parametric paired, two sided
test for the null hypothesis that states the median difference in paired samples is
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Table 1.1: Comparison of AUC and F1-score in over ten stratified 5-fold cross-
validations
Model AUC F1-Score
Logistic LASSO 0.5899±0.020 0.3347±0.025
Random LASSO 0.6209±0.020 0.3370±0.020
SVM 0.6337±0.015 0.3446±0.015
Dropout NN 0.6408±0.014 0.2957±0.025
PASNet 0.6622±0.013 0.3978±0.016
zero. Specifically, the null hypothesis is that the benchmark classifier has equal or
better performance than our proposed algorithm. Table 1.2 shows the performance
of PASNet is significantly better than others, where the null hypotheses are rejected
at the 5% significance level (p-value < 0.05). Hence, the outperformance of PASNet
was statistically significant compared to the benchmark classifiers.
Table 1.2: The Wilcoxon signed-rank tests for comparing PASNet with the Bench-
mark Classifiers
W Statistic P-value
PASNet vs. Dropout NN 146.5 2.13e-06
PASNet vs. RBF-SVM 137.0 1.35e-06
PASNet vs. Random LASSO 45.0 1.06e-08
PASNet vs. Logistic LASSO 43.0 9.52e-09
SVM and Dropout NN showed a higher AUC than LASSO logistic regression
and Random LASSO, probably because of their capability of capturing nonlinear
effects of genes. Compared to Dropout NN, PASNet is a relatively thin network,
where the connections between layers are very sparse. However, PASNet interestingly
produced higher performance than Dropout NN. It shows that PASNet builds a robust
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network model, which is simplified to represent the biological processes for prognosis
prediction by incorporating biological prior knowledge.
1.5 Model Interpretation in GBM
Although PASNet yielded competitive predictive performance in the experi-
ments, a more promising contribution of PASNet is in the model’s interpretability. In
this section, we demonstrate a plausible biological mechanism inferred by PASNet for
long-term survival prediction in GBM. The graphical representations of the PASNet
model are illustrated in Figures 1.4–1.6 in the top-down order. The heatmaps were
generated by sorting the weights and node values of LTS, and positive and negative
weight values are colored in red and blue, respectively.
First, Figure 1.4 manifests the posterior probability of the samples in the clinical
outcomes. The dark block on the top shows the output node values (−log2(node value))
of the LTS samples, while the remaining ones are non-LTS samples. The weight
values of the connections from hidden nodes to the output nodes are depicted in
Figure 1.5(a), where dropped connections are colored in white. The figure reveals
distinct patterns of weights (opposite signs) to the two output neurons. Note that
there are hidden nodes disconnected to the neurons in the output layer (colored in
white) by sparse coding, which shows that the hidden nodes are insignificant.
The hidden node values of the samples are shown in Figure 1.5(b). The values of
the hidden nodes indicate the intensity of the group effects on the pathways, which are
connected to the hidden nodes. For instance, the first 16 hidden nodes in Figure 1.5(b)
show distinguishable intensities on LTS and non-LTS patients. The LTS patients
present significant intensities of the group effects of the 16 pathways while non-LTS
patients show significant lower values.
The weights between the pathway nodes and the hidden nodes are exhibited
in Figure 1.5(c), and the top-10 ranked pathways among them are zoomed in Fig-
ure 1.6(a). It appears that a small number of pathways mainly contribute to the
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hidden nodes simultaneously, which implies that the cohort of the pathways may
be candidates of prognostic biomarkers in long-term survival of GBM. The top-10
ranked pathways include signaling by GPCR, GPCR downstream signaling, innate
immune system, adaptive immune system, metabolism of carbohydrates, transmem-
brane transport of small molecules, developmental biology, metabolism of proteins,
class A/1 (rhodopsin-like receptors), and axon guidance. Most of the pathways are
referred to as significant pathways in GBM in biological literature. The pathways and
the references are listed in Table 1.3. Since the top-10 ranked pathways are all large
(gene numbers > 200), we further explored small pathways as well. Class B/2 (Se-
cretin family receptors) pathway which includes 88 genes is ranked 14th. One of the
subgroups in Class B/2 family is categorized as brain-specific angiogenesis inhibitors
that are growth suppressors of glioblastoma cells [46]. Hence, Class B/2 pathway may
play an important role in inhibition of GBM.
The genes of the pathways are illustrated by the weight values in Figure 1.6(b).
Since the connections between the gene layer and the pathway layer are given by
pathway databases, e.g., Reactome, they are very sparse. It also shows that multi-
ple pathways share genes in common. The genes, which are most frequently shown
in the ten pathways, include CDC42, PRKCQ, RAC1, AKT1, AKT2, AKT3, C3,
CREB1, GRB2, HRAS, KRAS, NRAS, PRKACA, PRKACB, PRKACG, RAF1, and
YWHAB, where CDC42, PRKCQ, and RAC1 are shown in six pathways and others
are in five pathways. Among them, several genes have been reported as biomarkers
in GBM. For instance, AKT1, AKT2, and AKT3, belonging to the five pathways of
signaling by GPCR, GPCR downstream signaling, innate immune system, adaptive
immune system, and developmental biology, are three isoforms of AKT in PI3K/AKT
pathway, which is an important drug target in many cancers including GBM [54]. In
particular, AKT2 is a well-known proto-oncogene that promotes the growth of tumors












































































































































































































































































































































































































































































































































Finally, we demonstrate a hierarchical representation of genes and pathways in
PASNet. In Figure 1.7(a), PASNet is partially visualized, where positive and nega-
tive weights are colored in red and blue respectively. The pathways are represented
by the corresponding genes in the pathway layer, and then the nonlinear effects of
the pathways are described in the hidden layer. The hierarchical representations can
be captured in the output layer, which produces a posterior probability for progno-
sis prediction. Although we considered a single hidden layer to simplify the model
with HDLSS data in this study, multiple hidden layers may be able to capture the
biological processes and their effects more accurately if a sufficient number of sam-
ples are available. Figure 1.7(b) – (c) illustrate distinctive representations of LTS
and non-LTS samples in PASNet. The color of nodes in the figures shows the values
computed with LTS/non-LTS samples in average. Note that node values between
the pathway layer and the output layer are between zero and one. The node with
a high value may be a potential prognostic biomarker in the group. Figure 1.7(b)
shows that pathways including aquaporin-mediated transport, signaling by BMP, and
cytokine signaling in immune system are activated with LTS samples. The second
node in the hidden layer is triggered by the active pathways, and the hidden node
activates the LTS node in the output layer. On the other hand, Figure 1.7(c) shows
that additional pathways of signaling by GPCR and innate immune system are also
activated for non-LTS samples. The other two hidden nodes take the active pathways
into account, and they activate the non-LTS node in the output layer. Hence, the
two pathways of signaling by GPCR and innate immune system may be potential
prognostic biomarkers for predicting LTS/non-LTS. Pathway of signaling by GPCR
has been investigated as a potential therapeutic target to inhibit the progression of
glioblastomas. [47]. Activating the innate immune system, i.e. immunotherapy, is
a promising strategy for the treatment of GBM [57]. Vascular endothelial growth
factor (VEGF), a modulator of the innate immune system, is reported crucial for the
tumor progression [49]. Moreover, aquaporin-mediated transport, signaling by BMP,
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and cytokine signaling in immune system may play an important role in GBM, since
they are shown in common as active in both LTS and non-LTS. Note that the activa-
tion/inactivation of a node in PASNet does not directly represent biological activation
in the system, whereas it indicates different states of the biological components in the
groups.
1.6 Conclusions
In this chapter, we proposed pathway-associated sparse deep neural network
for prognosis predictions (long-term survivals in GBM in this study). PASNet builds
a network model by leveraging prior biological knowledge of pathway databases and
by taking hierarchical nonlinear relationships of biological processes into account. To
improve the model interpretability, PASNet introduces sparse coding. Moreover, we
developed a training strategy to avoid the overfitting problem with HDLSS data and
the imbalanced problem.
To investigate the performance of PASNet, we used gene expression data of
GBM patients in TCGA. PASNet was assessed by comparing the predictive per-
formance with support vector machine, random LASSO, LASSO logistic Regression,
and neural network with dropout that have been widely used for prognosis prediction.
PASNet outperformed them with respect to both AUC and F1-score in the multiple
stratified 5-fold cross-validation experiments. Furthermore, we discussed how PASNet
can describe the biological system of GBM.
PASNet is the first deep neural network-based model that represents hierarchical
representations of genes and pathways and their nonlinear effects, to the best of
our knowledge. Additionally, PASNet would be promising due to its flexible model







































































































































































































































































































































Figure 1.3: ROC Curves. PASNet produces the highest AUC of 0.6622 while the



















Figure 1.4: Graphical representation of the output node values over the samples by
PASNet. LTS samples obtain higher node values in LTS node than non-LTS samples.
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Figure 1.5: Graphical representation among the output layer, hidden layer, and path-
way layer in PASNet. (a) The weights between the hidden layer and the output layer.
Hidden nodes are sorted in a descending order. (b) The node values in the hidden
layer. The horizontal dotted lines indicates LTS/non-LTS samples. The vertical dot-
ted lines indicates LTS/non-LTS samples are significantly distinguished by top 16
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Figure 1.6: Graphical representation of the 10 top-ranked pathways by PASNet. (a)
The absolute weights between the 10 top-ranked pathway nodes and the hidden layer.
It is a zoom-in view of Figure 1.5(c). (b) Weights between the gene layer and the 10

































Figure 1.7: Hierarchical representation of pathways in PASNet. (a) PASNet is par-
tially visualized showing the five pathways. Distinct neural network activations be-
tween LTS (b) and non-LTS (c) are shown via PASNet. The nodes of the neural
network of (b) and (c) correspond to (a). For instance, the nodes in the pathway
layer of (b) and (c) represent signaling by GPCR, innate immune system, aquaporin-
mediated transport, signaling by BMP, and Cytokine signaling in immune system.
The pathways of signaling by GPCR and innate immune system are inactive with
LTS patients, whereas the both pathways are active with non-LTS patients.
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CHAPTER 2
INTERPRETABLE DEEP NEURAL NETWORK FOR CANCER SURVIVAL
ANALYSIS BY INTEGRATING GENOMIC AND CLINICAL DATA
2.1 Background
Dissecting complex biological processes associated to clinical outcomes (e.g.,
patients survival time) at the cellular and molecular level provides in-depth biological
insights not only for developing new treatments for patients, but also for accurate
prediction of clinical outcomes [58]. Advanced molecular high-throughput sequencing
platforms produce high-dimensional genomic data (e.g., gene expression data) that
can provide rich biological descriptions of molecular profiles of human diseases (e.g.,
cancer) as well as supporting clinical decision-making [59].
Survival analysis estimates survival distribution and investigates the effects of
biological and clinical features on a patient’s survival time, while handling censored
data. The most widely used method for survival analysis is the Cox Proportional
Hazards model (Cox-PH), a semi-parametric model that computes the effects of co-
variates on the risk of event [60, 61]. Cox-PH assumes that the linear combination of
patients covariates may be associated with the hazard function (instantaneous rate
of occurrence of the event).
However, traditional Cox-PH models have limitations: (1) analyzing high-
dimension, low-sample size (HDLSS) data or (2) highly nonlinear data. Training
models with HDLSS data is a challenging problem in bioinformatics, because most
biological data have many more features (p) than the number of samples (n), i.e.,
p >> n. HDLSS data often make model training infeasible [62]. Thus, low dimen-
sional data, such as clinical data (e.g., age, sex, and body-mass-index), have been
analyzed with the Cox-PH model for survival analysis. However, recently, an in-
creasing number of research studies have examined high-dimensional genomic data
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to unveil the molecular mechanisms that cause different survival rates. To tackle
the HDLSS problem on the Cox-PH model, feature selection techniques and regu-
larization have been considered. Lasso (L1-norm) and elastic net penalizations were
introduced in the Cox-PH model [63, 64, 65, 66], whereas in another study a feature
selection approach was performed to reduce the number of covariates [67].
The relationship between genomic data and a patient’s survival is often highly
nonlinear in complex human diseases, whereas a hazard in the Cox-PH model assumes
linear relationships between the predictors and a function of the outcome and time
of the outcome. Kernel trick is a standard solution to convert nonlinear effects to
linear, for linear learning algorithms. Kernel Cox-regression was proposed to capture
nonlinear effects between gene expression data and survival data [68]. In the kernel
Cox-regression model, regularized Cox-PH was considered in a reproducing kernel
Hilbert space. Survival SVM model was developed with sparse regularization for
high-dimensional and nonlinear data [69]. However, it is difficult to identify the
optimal kernel function of the data, because a kernel function has to be specified in
advance.
Lately, deep learning approaches have been successfully adapted due to the
capability of modeling highly nonlinear systems and the flexibility of architecture
design. In survival analysis, a number of deep learning approaches have been devel-
oped coupled with a Cox proportional hazards output layer. DeepSurv introduced
a Cox proportional hazards function into a deep fully-connected feed-forward neu-
ral network for survival analysis and personalized treatment recommendation [70],
and it showed competitive performance with Cox-PH and random survival forests.
However, DeepSurv considered only low-dimensional clinical data, where only a small
number of covariates (p < 20) were examined on simulation data and clinical data.
Cox-nnet was constructed based on an artificial neural network with a Cox propor-
tional hazards node in the output layer [71]. High-throughput transcriptomics data
of RNA-Seq were introduced to Cox-nnet, and it produced better performance than
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Cox-proportional hazards regressions, random survival forests, and CoxBoost. Cox-
nnet reported that the high-level representations of gene expression at the top nodes
of the hidden layer are correlated to survival rates, and each of the nodes in the
hidden layer may implicitly reflect biological processes. SurvivalNet optimizes deep
survival models via Bayesian optimization based on Cox-nnet for high-throughput
different types of genomic data such as gene expressions, protein expressions, copy
number variations, and mutations [72]. SurvivalNet automatically found the optimal
network (e.g., numbers of layers and nodes), and the performance of SurvivalNet was
slightly better than Cox elastic net (Cox-EN) and random survival forests when the
dimension of the data is high. The risk backpropagation analysis enabled SurvivalNet
to be interpretable by generating risk scores for each feature.
However, applying deep learning approaches to high-dimensional genomic data
for survival analysis is still challenging due to (1) the problem of overfitting when
training a deep learning model with HDLSS data and (2) lack of explicit model
interpretation. Deep learning typically requires a large number of samples, since deep
neural network models involve a number of parameters. Particularly, when training
a deep learning model with HDLSS data, gradients tend to have high variance in
backpropagation, which consequently causes model overfitting. Both Cox-nnet and
SurvivalNet introduced only significant genomic data by feature selection approaches
to avoid the overfitting problem. In order to tackle the HDLSS problem in deep
learning, dimension reduction techniques were employed to reduce the dimension of
the input data, and the results were introduced to a neural network [32]. Deep
Feature Selection was developed to identify discriminative features in a deep learning
model [33]. Deep Neural Pursuit trained a small-sized sub-network and computed
gradients with low variance for feature selection [30].
Conventionally, deep neural networks consist of multiple fully-connected layers,
which make it difficult to interpret. In survival analysis, model interpretation (e.g.,
identifying prognosis factors) is often more important than simply predicting patient
29
survival with high accuracy. However, fully-connected hidden layers lack to represent
explicit biological components. Also, biological processes may involve only a small
number of biological components rather than all input features. Thus, the capability
of explicit model interpretation with sparse deep neural networks is highly desired in
survival analysis.
Furthermore, high-level biological interpretation (e.g., hierarchical relationship
between molecular pathways) has seldom been highlighted, whereas biological in-
terpretation at low levels (e.g., gene expression level) has been often considered.
Pathway-based model interpretation can provide better biological intuitive and inter-
pretable solutions. Pathway-based analysis often produces significantly reproducible
power in genomic study by incorporating well-known biological knowledge. For in-
stance, higher-order functional representation of pathway-based metabolic features
provided robust and highly reproducible biomarkers for breast cancer diagnosis [9].
Complex biological systems may involve hierarchical relationships between bio-
logical pathways. The hierarchical linkages of biological pathways may cause different
survival rates. For instance, the hierarchical representation with receptor pathways
and gene ontology was studied for antiviral signaling [73]. Therefore, the incorpora-
tion of the effects of inhibition and propagation of a pathway component to others in
deep learning can allow the model to be interpretable.
Data integration of multiple types of data (e.g., multi-omics data or clinical
data) in deep learning model is also challenging. A number of studies have reported
that leveraging multi-omics and clinical data improves predictive performance in sur-
vival analysis [72, 1, 74]. A naive approach to integrate multi-omics data is to combine
all types of data into a single matrix and perform survival analysis [75, 72]. The ap-
proach assumes that the heterogeneous data can be represented by an augmented
matrix form. However, the augmented matrix causes problems: (1) generates much
higher dimension of HDLSS data, (2) makes the sample size smaller due to missing
values, and (3) ignores data types having a smaller number of covariates. Note that
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multi-omics data on The Cancer Genome Atlas (TCGA) present substantial missing
values; e.g., 160 samples of mRNA-Seq are available, while 595 clinical samples are
in glioblastoma multiforme (GBM) dataset in TCGA.
In this chapter, we propose a novel method, Cox-PASNet, a pathway-based
sparse deep neural network, for survival analysis integrating high-dimensional genomic
data and clinical data. Our main contributions of Cox-PASNet for survival analysis
are:
• to explicitly model nonlinear and hierarchical relationships in a biological path-
way level,
• to enable one to interpret the model, where nodes in layers correspond to bio-
logical components of genes and pathways,
• to integrate clinical data in a deep learning model, and
• to provide an efficient solution to train the complex neural network model with
HDLSS data without overfitting problem.
2.2 Methods
2.2.1 The Architecture of Cox-PASNet
We introduce our proposed model, Cox-PASNet, a pathway-based sparse deep
neural network for survival analysis with genomic and clinical data. Cox-PASNet
combines a Cox proportional hazards regression with a deep neural network, incorpo-
rating prior knowledge of biological pathways. The architecture of Cox-PASNet (see
Figure 2.1) is comprised of (1) a gene layer, (2) a pathway layer, (3) multiple hidden
layers, (4) a clinical layer, and (5) a Cox layer.
Gene Layer
The gene layer is an input layer of Cox-PASNet introducing gene expression
data with n patient samples of p gene expressions. For pathway-based analysis, only

















Figure 2.1: The architecture of Cox-PASNet. The structure of Cox-PASNet is con-
structed by a gene layer (an input layer), a pathway layer, multiple hidden layers, a
clinical layer (additional input layer), and a Cox layer.
Pathway Layer
The pathway layer represents biological pathways where a node indicates a
specific biological pathway. The pathway layer incorporates prior biological knowledge
so that the model can be biologically interpretable. Pathway databases (e.g., KEGG
and Reactome) contain a set of genes that are involved in a pathway, and each pathway
characterizes a biological process. The knowledge of the given association between
genes and pathways explicitly forms sparse connections between the gene layer and
the pathway layer in Cox-PASNet, rather than fully-connecting the layers.
To implement the sparse connections between the gene and the pathway lay-
ers, we consider a binary bi-adjacency matrix. Given pathway databases containing
pairs of m genes and n pathways, the binary bi-adjacency matrix (A ∈ Bn×m) is
constructed, where an element aij is one if gene j belongs to pathway i, otherwise
zero, i.e., A = {aij|1 ≤ i ≤ n, 1 ≤ j ≤ m} and aij = {0, 1}.
Hidden Layers
The hidden layers model the nonlinear and hierarchical effects of pathways.
Node values in the pathway layer indicate the active/inactive status of a single path-
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way in a biological system, whereas the hidden layers show the interactive effects of
multiple pathways. The deeper hidden layer expresses the higher level representations
of biological pathways.
Clinical Layer
The clinical layer introduces clinical data to the model separately from genomic
data. The dimension of clinical data is usually much smaller than genomic data, so
clinical data tend to be easily ignored if introducing them to the input layer with
genomic data. In Cox-PASNet, the complex genetic effects of gene expression data
are captured from the gene layer to the hidden layers, whereas the clinical data are
directly introduced into the output layer along with the highest-level representation
of genomic data (i.e., node values on the last hidden layer). Therefore, Cox-PASNet
takes the effect of genomic data and clinical data separately into account in the neural
network model.
Cox Layer
The Cox layer is the output layer that has only one node. The node value
produces a linear predictor, a.k.a. Prognostic Index (PI), from both genomic and
clinical data, which is introduced to a Cox-PH model. Note that the Cox layer has
no bias node according to the design of the Cox model.
Furthermore, we introduce sparse coding so that the model can be biologically
interpretable and mitigate overfitting. In a biological system, a few biological com-
ponents are involved in biological processes. The sparse coding enables the model to
include only significant components for better biological model interpretation. Sparse
coding is applied to the connections from the gene layer to the last hidden layer by
mask matrices. The details of sparse coding are described in Section 2.2.4.
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2.2.2 Objective Function
In order to perform Cox proportional hazards regression on the Cox layer, Cox-













where Θ = {β,W} is a set of parameters, β is the Cox proportional hazards coeffi-
cients (weights between the last hidden layer and the Cox layer), W is a union of the
weight matrices on the layers before the Cox layer, and hI is the integrative layer that
integrates the second hidden layer’s outputs and the clinical inputs from the clinical
layer. E is a set of uncensored samples, nE is the total number of uncensored samples,
and R(Ti) = {i|Ti ≥ t} is a set of samples at risk of failure at time t. ‖W‖2 and ‖β‖2
are the L2-norms of W and β respectively, and λ is a regularization hyperparameter
to avoid overfitting (λ > 0).
2.2.3 Training Cox-PASNet
We propose an optimization strategy to train Cox-PASNet with HDLSS data
along with L2 regularization in the objective function. We optimize the model by par-
tially training small sub-networks with sparse coding. Training a small sub-network
guarantees the feasible optimization with a small set of parameters in each epoch.
The overall training flow of Cox-PASNet is illustrated in Figure 2.2. Layers are
initially set to be fully connected, where weights and biases are randomly initialized.
Particularly, the connections between the gene layer and the pathway layer are forced
to be sparse by the bi-adjacency matrix, and the Cox layer includes no bias node.
A small sub-network is randomly chosen by a dropout technique in the hidden
layers excluding the Cox layer (Figure 2.2a). Then, the weights and the biases of the
sub-network are optimized by backpropagation. Once training of the sub-network





























Figure 2.2: Training of Cox-PASNet with high-dimensional, low-sample size data. (a)
A small sub-network is randomly chosen by a dropout technique in the hidden layers
and trained. (b) Sparse coding optimizes the connections within the small network.
within the small network that do not contribute to minimizing the loss. In Figure 2.2b,
the connections and the nodes dropped by sparse coding are marked with bold and
dashed lines. The algorithm of Cox-PASNet is briefly described in Algorithm 2.
Algorithm 2 Training of Cox-PASNet
1: Initialize weights W(`), biases b(`), and β
2: W(0) ←W(0) ?M(0)
3: repeat
4: Select a small sub-network via dropout
5: Train the sub-network




Sparse coding is implemented by mask matrices. A binary mask matrix M
controls a sparsity level of each layer on the sub-network, where an element indicates
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(W(`) ?M(`))h(`) + b(`)
)
, (2.2)
where ? denotes an element-wise multiplication operator, and a(·) is a nonlinear
activation function (e.g., sigmoid or Tanh). h(`) is the outputs on the `-th layer, and
W(`) and b(`) are a weight matrix and a bias vector, respectively, with 1 ≤ ` ≤ L−2,
where L is the number of layers.
In particular, an element of M is set to one if the absolute value of the corre-
sponding weight is greater than threshold s(`), otherwise it is zero. Note that the mask
between the gene layer and the pathway layer, i.e., M(0), is determined by the bi-




(`)| ≥ s(`)), if ` 6= 0
A, if ` = 0.
(2.3)
The optimal sparsity level (s(`)) is estimated on each layer in the sub-network to
generate the mask matrix. For efficient approximation of the optimal sparsity level,
cost scores are computed with various finite sparsity levels in a range of s = [0, 100)
where zero generates a fully-connected layer while 100 shows disconnected layers.
Then, we approximate the cost function with respect to sparsity levels by applying a
cubic-spline interpolation to the cost scores computed by the finite set of s. Finally,
the sparsity level that minimizes the cost score is considered for the optimal sparsity
level. The optimal s(`) is approximated on each layer individually in the sub-network.
The individual optimization of the sparsity on each layer represents different levels of




In this study, we considered GBM and ovarian serous cystadenocarcinoma
(OV) to assess Cox-PASNet. GBM is the most aggressive malignant type of brain
tumor, which shows poor prognosis [37]; OV is one of the most common cancer
types among women in the world, and OV is usually diagnosed at a late stage [76].
Gene expression and clinical data of GBM and OV were obtained from the TCGA
(http://cancergenome.nih.gov). The samples that lack survival time or survival status
were filtered out.
The prior knowledge of biological pathways was taken from the Molecular
Signatures Database (MSigDB) [40, 41, 42], where KEGG and Reactome pathway
databases were considered for the pathway-based analysis. We excluded small path-
ways (i.e., less than fifteen genes) and large pathways (i.e., over 300 genes), since
small pathways are often redundant with other larger pathways and large pathways
are related to general biological pathways rather than specific to a certain disease [43].
Moreover, only the genes that belong to at least one pathway were investigated.
For the integrative analysis, we included the clinical information of both GBM
and OV patients. We incorporated only age in the clinical layer of Cox-PASNet,
because age has been reported as a significant covariate for prognostic prediction in
GBM [1] and most other clinical data have substantial missing values. Although
Karnofsky Performance Score (KPS) is also reported as significant as well as age,
KPS is highly correlated to age, and there are many missing values. Finally, we used
5,404 genes, 659 pathways, and clinical data of age from 523 GBM samples and 532
OV samples.
2.3.2 Experimental Design
Cox-PASNet was assessed by comparing the performance with Cox-EN [65],
Cox-nnet [71], and SurvivalNet [72]. The performance of the four models was eval-
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uated by C-index, which is a non-parametric metric that calculates concordance be-
tween predicted and actual survival curves. The value range of C-index is between
zero and one, where one indicates a perfect model prediction and 0.5 means a random
guess.
The dataset was randomly split into training (64%), validation (16%), and test
(20%) data, while preserving the proportion of the censor status between censored
and uncensored samples. The gene expression and clinical data in the training data
were standardized to mean of zero and standard deviation of one. The validation and
the test data were normalized with the mean and standard deviation from the training
data. Each model was trained by the training data; the optimal hyper-parameters
were obtained with the validation data; and the model performance was evaluated by
the test data. The experiments were repeated over twenty times for reproducibility
of model performance.
Cox-PASNet followed a modern deep learning design. We used the Tanh func-
tion as the activation function. Both dropout and L2 regularizations were considered.
Adaptive Moment Estimation (Adam) was performed for the optimization to ap-
proximate first-order gradients [44]. The optimal initial learning rate (η) and the L2
regularization (λ) were estimated by the grid search technique. η and λ that minimize
the cost function with validation data were selected as the optimal hyper-parameters.
Dropout rates were empirically set to be 0.7 and 0.5 for the pathway layer and the fol-
lowing hidden layers, respectively. The open source code of Cox-PASNet implemented
by PyTorch is available at https://github.com/DataX-JieHao/Cox-PASNet.
Cox-EN models were implemented using Glmnet Vignette package in Python [65].
The hyper-parameters of α and λ were optimized by grid search. We considered val-
ues of α between 0 and 1 with a step of 0.01 and 200 λ values. Then, Cox-EN
was performed with the optimal hyper-parameters that minimize the cost function.
Cox-nnet was conducted based on open source codes provided by the authors. The
tuning setting of the model followed their recommendation. Grid search for L2 was
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applied. The optimal hyper-parameters of SurvivalNet were optimized by Bayesian
Optimization technique, BayesOpt [77]. We also considered the hyper-parameters of
L1 and L2 regularizations for the Bayesian optimization in addition to their default
setting. SurvivalNet was carried out by its open source in GitHub.
For the data integration, both the clinical data of age and gene expression data
were combined into an input matrix and introduced to Cox-EN, SurvivalNet, and
Cox-nnet at the input level for the experiments, whereas Cox-PASNet introduced gene
expression data into the gene layer and clinical data into the clinical layer separately.
2.3.3 Experimental Results
The experimental results with GBM and OV data are shown in Figure 2.3 and
Table 2.1–2.3. Cox-PASNet showed the highest C-index of 0.6347 ± 0.0372 in GBM,
whereas the second highest C-index of 0.5903 ± 0.0372 was shown in Cox-nnet (Fig-
ure 2.3a and Table 2.1). Cox-nnet is a simplified model of SurvivalNet that includes
only a hidden layer. On the other hand, SurvivalNet is a generalized fully-connected
neural network model for survival analysis with Cox-model, where the optimal archi-
tecture is determined by Bayesian optimization technique. Cox-nnet reported that
the simple neural network architecture often produces better performance than deeper
networks [71]. Cox-EN produced a C-index of 0.5151 ± 0.0336, which is close to a
random guess. It may be due to the highly nonlinear HDLSS data of 5,404 features of
523 samples. The statistical significance of the performance was assessed by Wilcoxon
rank-sum test. The distributions of C-index scores produced by Cox-PASNet were
significantly higher than others in Table 2.2.
Moreover, we evaluated Cox-PASNet with OV data. Cox-PASNet showed the
highest C-index of 0.6343 ± 0.0439 as well; Cox-nnet retained the second rank with
C-index of 0.6095 ± 0.0356; Cox-EN was the last place with C-index of 0.5276 ±
0.0482 (Figure 2.3b and Table 2.3). The statistical testing of Wilcoxon rank-sum test
showed that Cox-PASNet also statistically outperformed others in OV in Table 2.4.
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Table 2.1: Comparison of C-index with GBM in over 20 experiments
Model C-index
Cox-EN 0.5151 ± 0.0336
Cox-nnet 0.5903 ± 0.0372
SurvivalNet 0.5521 ± 0.0295
Cox-PASNet 0.6347 ± 0.0372
Table 2.2: Statistical assessment with GBM
Wilcoxon rank-sum test (P-value)
Cox-PASNet vs. Cox-EN 8.85e-05∗
Cox-PASNet vs. Cox-nnet 4.49e-4∗
Cox-PASNet vs. SurvivalNet 1.40e-4∗
∗ shows the statistical significance with significance level = 0.05.
Cox-PASNet shares the cost function of negative log partial likelihood with Cox-
nnet and SurvivalNet. However, Cox-PASNet constructs the neural network based
on prior knowledge of biological pathways, and the biologically inspired architecture
produced better performance reducing noise that comes from the data complexity.
Cox-PASNet also trains the model with sub-networks to avoid overfitting problem
with HDLSS data. The outstanding performance supports the contributions of the
new architecture Cox-PASNet and the training strategy.
2.4 Model Interpretation in GBM
For the biological model interpretation of Cox-PASNet, we re-trained the model
with the optimal pair of hyper-parameters from 20 experiments using all available
GBM samples. The samples were categorized into two groups of high-risk and low-
risk groups by the median Prognostic Index (PI), which is the output value of Cox-
PASNet. The node values of the two groups in the integrative layer (i.e., the second
hidden layer (H2) and the clinical layer) and the pathway layer are illustrated in
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Table 2.3: Comparison of C-index with OV in over 20 experiments
Model C-index
Cox-EN 0.5276 ± 0.0482
Cox-nnet 0.6095 ± 0.0356
SurvivalNet 0.5614 ± 0.0524
Cox-PASNet 0.6343 ± 0.0439
Table 2.4: Statistical assessment with OV
Wilcoxon rank-sum test (P-value)
Cox-PASNet vs. Cox-EN 1.03e-4∗
Cox-PASNet vs. Cox-nnet 0.04∗
Cox-PASNet vs. SurvivalNet 2.93e-4∗
∗ shows the statistical significance with significance level = 0.05.
Figure 2.4 and Figure 2.5, respectively. In Figure 2.4a, the node values of 31 covariates
(30 from the genomic data and age from the clinical data) were sorted by the average
absolute partial derivatives with respect to the integrative layer. Age (the first column
in Figure 2.4a) is shown as the most important covariate in Cox-PASNet with GBM
data in terms of the partial derivatives.
The top ranked covariates show distinct distributions between high-risk and
low-risk groups. For instance, the first three covariates in H2 (the 2nd, 3rd and 4th
columns in Figure 2.4a) were activated in the high-risk group, but inactivated in
the low-risk group. Moreover, we performed logrank test by grouping node values
of the covariate into two groups individually again by their median. The -log10(p-
values) computed by logrank test are depicted in the above panel aligning with the
covariates in Figure 2.4a. The red triangle markers show significant covariates (-
log10(p-value) > 1.3), whereas the blue markers show insignificant ones. The logrank
tests revealed that the top ranked covariates by the absolute weight are associated to
survival prediction. Figure 2.4b – 2.4c present Kaplan-Meier curves for the top two
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covariates, where survivals between the two groups are significantly different. Thus,
the top ranked covariates can be considered as prognostic factors.
In the same manner, the nodes in the pathway layer are partially illustrated in
Figure 2.5. The heatmap in Figure 2.5a depicts the top 10 pathway node values of
the high-risk and low-risk groups, where the pathway nodes are sorted by the average
absolute partial derivatives with respect to the pathway layer. We also performed
logrank tests on each pathway node, and 304 out of 659 pathways were statistically
significant on the survival analysis. The two top-ranked pathways were further in-
vestigated by Kaplan-Meier analysis, shown in Figure 2.5b–2.5c. The Kaplan-Meier
curves of the two top-ranked pathways imply the capability of the pathway nodes as
prognostic factors.
The statistically significant nodes in the integrative layer and the top ten ranked
pathway nodes are visualized by t-SNE [78] in Figure 2.6, respectively. The nonlin-
earity of the nodes associated with PI is illustrated. The integrative layer represents
the hierarchical and nonlinear combinations of pathways. Thus, the more distinct
associations with survivals are shown in the integrative layer than the pathway layer.
The ten top-ranked pathways by the partial derivatives are listed with related
literature in Table 2.5. The p-values in the table were computed by logrank test
with the pathway node values of the two groups of high and low risks. Among them,
five pathways were reported as significant pathways in biological literature of GBM.
Jak-STAT signaling pathway, which is usually called as an oncopathway, is activated
for the tumor growth of many human cancers [79]. Inhibition of Jak-STAT signaling
pathway was shown to reduce the malignant tumors using animal models of glioma.
Neuroactive ligand-receptor interaction was explored as one of the most significant
pathways in GBM [80]. PI3K cascade is also a well-known pathway that is highly
involved in proliferation, invasion, and migration in GBM [81].
The ten top-ranked genes by partial derivatives with respect to each gene are
listed with their p-values and related literature in Table 2.6. PRL is known as be-
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ing associated with occurrence of neoplasms and central nervous system neoplasms,
and the assessment with PRL expression in primary central nervous system tumors
was investigated [86]. MAPK9 was identified as a novel potential therapeutic marker
along with RRM2 and XIAP, which is associated with biological pathways involved
in the carcinogenesis of GBM [87]. IL22 was reported to promote the malignant
transformation of bone marrow-derived mesenchymal stem cells, which exhibit po-
tent tumoritropic migratory properties in tumor treatment [88]. FGF5 contributes to
the malignant progression of human astrocytic brain tumors as an oncogenic factor
in GBM [89]. The activation of JUN along with HDAC3 and CEBPB may form
resistance to chemotherapy and radiation therapy of hypoxic GBM, and the down-
regulation of the genes appeared to inhibit temozolomide on hypoxic GBM cells [90].
Low expression of DRD5 was presented as being associated with relatively superior
clinical outcomes in glioblastoma patients with ONC201 [91]. HTR7 involved in neu-
roactive ligandreceptor interaction and calcium signaling pathway was reported to
contribute the development and progression of diffuse intrinsic pontine glioma [92].
It is worth noting that only IL22 and FGF5 are statistically significant (i.e.,
p-value < 0.05) by logrank test on each gene, which means that only the two genes
can be identified as significant prognostic factors by conventional Cox-PH models.
However, other genes such as PRL, MAPK9, JUN, DRD5, and HTR7 have been bio-
logically identified as significant prognostic factors, even though significantly different
distributions are not found on gene expression (i.e., p-value ≥ 0.05). The average ab-
solute partial derivatives with respect to each gene measure contribution to patients’
survival through the pathway and hidden layers in Cox-PASNet when gene expres-
sion varies on the gene. Therefore, the gene biomarker identification by Cox-PASNet
allows one to capture significant genes nonlinearly associated to patients’ survival.
Figure 2.7 illustrates the overall hierarchical representation of biological path-
ways in Cox-PASNet. A pathway node is represented by nonlinear effects of the
associated gene nodes, and a hidden node expresses the high-level representation of
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a set of pathways. The following hidden layers describe the hierarchical representa-
tion of the previous hidden nodes. Then, the last hidden nodes are introduced to a
Cox-PH model with clinical data.
A pathway node value shows active or inactive status of the corresponding
pathway, which may be associated to different survivals (e.g., Jak-STAT signaling
pathway). The significance of the genes involved in the active pathway can be ranked
by the average absolute partial derivatives with repect to the gene layer (e.g., AKT1
and AKT3). A set of the active pathways are represented in an active node in the
following hidden layer, which improves the survival prediction. For instance, the
Kaplan-Meier plots of Node 19 and PI show more similar estimation of the survival
than Jak-STAT signaling pathway in Figure 2.7.
2.5 Conclusion
We developed a pathway-based sparse deep neural network, Cox-PASNet, for
survival analysis coupled with Cox-PH model on a deep neural network. Cox-PASNet
builds a neural network model that can describe nonlinear and hierarchical effects of
biological pathways and provide significant prognostic factors for accurate prediction
of patients’ survival. A new strategy to train the deep neural network model with
HDLSS data was also introduced in the paper. Cox-PASNet outperformed the current
cutting-edge survival methods such as Cox-nnet, SurvivalNet, and Cox-EN, and its
predictive performance was statistically assessed.
Negative log-partial likelihood with a single node in the output layer is consid-
ered in Cox-PASNet as Cox-nnet and SurvivalNet also adapted. Using Cox log-partial
likelihood function may raise several concerns with respect to the model assessment,
which is commonly applied in conventional Cox-PH models. One concern is if there is
multicollinearity in the last hidden layer’s nodes and the clinical layer’s node, which
are the covariates in the Cox-PH model. The covariates are hierarchically derived
high-level representations from gene expression data (inputs) rather than input data
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introduced to the model directly. Therefore, we used partial derivatives with respect
to inputs for the model assessment with neural network for identifying significant
genes or pathways. However, testing the multicollinearity would be a potential so-
lution to identify the optimal number of nodes. Another concern is how to assess
Cox-PASNet model fit by residuals, such as Martingale residuals and deviance resid-
uals. While the scope of our study is to develop neural network-based survival analysis
by incorporating Cox log-partial likelihood function, testing the fitness of a Cox-PH
model, eventually, would be beneficial to deep learning-based Cox-PH model.
Overall, Cox-PASNet constructs the neural network based on biological path-
ways with sparse coding. The genomic and clinical data are introduced to the model
separately for model interpretation. Cox-PASNet integrates clinical data as well as
genomic data. However, high-dimensional genomic data may cause bias in the inte-
gration due to the unbalanced size between genomic and clinical covariates. Further-
more, the incorporation of multi-omics data such as DNA mutation, copy number
variation, DNA methylation, and mRNA expression is essential to describe complex
human diseases involving a sequence of complex interactions in multiple biological
processes. A solution of integration of complex heterogeneous data would be desired




Figure 2.3: Experimental results with (a) GBM and (b) OV in C-index. Boxplots
of the C-index of (a) TCGA GBM dataset and (b) TCGA OV dataset using Cox-
EN, SurvivalNet, Cox-nnet, and Cox-PASNet. Each dataset was randomly split into
training (64%), validation (16%), and test (20%) data, while preserving the proportion
of the censor status between censored and uncensored samples. The experiments were




Figure 2.4: Graphical visualization of the node values in the second hidden layer
(H2) and the clinical layer. (a) Heatmap of the 31 nodes (i.e., thirty H2 nodes and
one clinical node). The horizontal dotted line indicates high-risk/low-risk samples.
The upper dot plot shows -log10(p-values) of logrank test between high-risk/low-risk
groups for each node. Red indicates statistical significance with logrank test, whereas
blue shows insignificance. The curve in the right panel shows prognostic indices (PI)





Figure 2.5: Graphical visualization of the node values in the pathway layer. (a)
Heatmap of the ten top-ranked pathway nodes. The horizontal dotted line indicates
high-risk/low-risk samples. The upper dot plot shows -log10(p-values) of logrank
test between high-risk/low-risk groups for the top ten ranked pathway nodes. Red
indicates statistical significance with logrank test, whereas blue shows insignificance.
The curve in the right panel shows prognostic indices (PI) with the corresponding























































































































































































































































































Table 2.6: Ten top-ranked genes in GBM by Cox-PASNet














Figure 2.6: Visualization of the top-ranked nodes by Cox-PASNet. (a) t-SNE plot of
the statistically significant nodes in the integrative layer (i.e. the second hidden layer























Figure 2.7: Hierarchical and associational feature representation in Cox-PASNet. For
instance, Jak-STAT signaling pathway shows active status, which is associated to
PI. The significance of the genes (i.e. AKT1 and AKT3) involved in the Jak-STAT
signaling pathway can be ranked by the average absolute partial derivatives with
respect to the gene layer. A set of the active pathways are represented in an active
Node 19 in the following hidden layers, which improves the survival prediction. Note
that the Kaplan-Meier plots of Node 19 and PI show more similar estimation of the
survival than Jak-STAT signaling pathway.
51
CHAPTER 3
GENE- AND PATHWAY-BASED DEEP NEURAL NETWORK FOR
MULTI-OMICS DATA INTEGRATION TO PREDICT CANCER SURVIVAL
OUTCOMES
3.1 Introduction
Data integration of multi-platform based omics data (e.g., genomics, proteomics,
and metabolomics) from biospecimens holds promise of improving survival prediction
and personalized therapies in cancer [93, 94]. The importance of integrative stud-
ies has been increasingly emphasized along with the rapid development of various
types of high-throughput multi-omics data. A large scale of multi-omics data sets
have been generated in various cancer projects, such as The Cancer Genome Atlas
(TCGA) and The Cancer Genome Project in Wellcome Trust Sanger Institute. In
particular, TCGA provides various types of omics data of more than 33 cancers, in-
cluding tissue exome sequencing, gene expression, Copy Number Alternation (CNA),
DNA variation, DNA methylation, and microRNA, as well as clinical data such as
race, tumor stage, and survival status and months of cancer patients.
Multi-omics data provide comprehensive descriptions of human genomes reg-
ulated by complex interactions of multiple biological processes such as genetic, epi-
genetic, and transcriptional regulation [95]. Thus, the integration of multi-omics
data can be leveraged to decipher complex mechanisms of human diseases and to
enhance cancer treatments based on genetic understanding of each patient in pre-
cision medicine. Specifically, genes are activated by sequential interactions of DNA
variations, CNA, histone modifications, transcription factors, DNA methylation, and
other genes in relevant pathways [96, 97]. CNA, which is a modified gene structure,
often alters downstream pathways or regulatory networks, and DNA methylation of-
ten reduces gene expression in a nearby gene when the methyl groups are added to
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the DNA. Hence, monozygotic twins discordance in disease is often caused due to
different CNA, although they have nearly identical genetic variants [98, 99].
Recently, multi-omics data have been widely incorporated in an increasing num-
ber of research projects in survival analysis, rather than using a single type of ge-
nomic data that most genomic research traditionally has analyzed. Multi-omics data
such as CNA, DNA methylation, and gene expresssion were integrated to identify
knowledge-driven genomic interactions with clinical outcomes of interest in ovarian
carcinoma [100]. The meta-dimensional models, which incorporate biological path-
ways with multi-omics data, enhanced the model interpretability in the biological
pathway level. A multi-block bipartite graph was proposed not only to identify intra-
and inter-block interaction effects of multi-omics data, but also to predict quantita-
tive traits such as gene expression and survival time [101]. SurvivalNet integrated
multi-omics data such as DNA mutation, CNA, protein, and mRNA along with clini-
cal information into a deep neural network to improve survival prediction of patients
in cancers [72]. Feature selection techniques were applied to each omics dataset sepa-
rately, and selected features of the multi-omics data and clinical data were combined
into a large augmented matrix in SurvivalNet. Another deep learning-based model in-
tegrated RNA-Seq, miRNA-Seq, and DNA methylation data to differentiate survival
groups in hepatocellular carcinoma [102]. Furthermore, the differential subgroups
identified several significant multi-omics features.
In this study, we propose a novel approach, called MiNet, to integrate multi-
omics data and clinical data using a pathway-based deep neural network for survival
analysis. Our previously published model, Cox-PASNet, which is a pathway-based
deep neural network for predicting survival outcome, has considered only gene ex-
pression data as well as clinical data [103]. The main contributions of MiNet are as
follows: (1) to introduce a multi-omics layer that represents gene-based interaction





























Figure 3.1: The architecture of MiNet
The rest of the paper is organized as follows. In Section 3.2, our proposed
model is elaborated in detail. The experimental setting and results are demonstrated
in Section 3.3. Section 3.4 discusses the model interpretation with biological findings,
while Section 3.5 concludes the discussion.
3.2 Methods
We propose a gene- and pathway-based multi-omics integrative deep neural
network (MiNet) to predict cancer survival outcomes. MiNet introduces a gene-based
multi-omics layer to integrate multi-omics data, leveraging the advantages of the
pathway-based neural network framework in Cox-PASNet [103]. The neural network
structure of MiNet follows a biological system, which is multi-layered with multi-omics
data and their interactions along with clinical features, by utilizing prior knowledge
of biological pathways. The biologically inspired neural network architecture provides
a rich interpretation of a biological system.
3.2.1 Multi-Omics Integration
Most studies have integrated multi-omics data by combining all types of omics
data to a single matrix and performed analysis, e.g., survival analysis. However, the
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consideration of the augmented multi-omics data as independent features lacks to
represent interaction effects of genomic and epigenomic data with gene expressions.
Note that CNA and DNA methylation often regulate transcriptional mechanisms of
genes, so some genes may be down- or up-regulated caused by interaction effects of
other omics data [104, 105].
We introduce a multi-omics layer that transfers gene-based interaction effects of
multi-omics data to the pathway-based neural network of Cox-PASNet [103]. MiNet
generates multi-omics features that include main and interaction effects of multi-omics
data on each gene. Then, MiNet inputs the multi-omics features to the multi-omics
layer followed by the gene layer that represents canonical gene expression level. Note
that the gene layer of MiNet consists of canonical gene expressions which are high-
level representations of gene-based multi-omics data, whereas Cox-PASNet introduces
gene expression data directly into the gene layer.
We consider cis-regulatory interaction effects of CNA and DNA methylation to










// Main effect of gene expression
// Main effect of CNA
// Main effect of DNA methlyation
// Interaction effect with CNA
// Interaction effect with DNA methlyation
, (3.1)
where gi, ci, and di are sample vectors of gene expression, CNA, and DNA methyla-
tion for the i-th gene, respectively. Note that we consider the genes that have at least
a gene expression feature. Then, canonical gene expression (g̃i) for the i-th gene is
expressed by:
g̃i = σ(xiwi), (3.2)
where wi is a weight vector, σ(·) is an activation function, and ⊗ is element-by-
element multiplication. The main or interaction effects are ignored if there is no
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CNA or DNA methylation associated to the i-th gene, so genes may have different
numbers of multi-omics features.
3.2.2 The Architecture of MiNet
The architecture of MiNet is composed of a multi-omics layer, a gene layer, a
pathway layer, multiple hidden layers, a clinical layer, and a Cox layer, as shown
in Fig. 3.1. The multi-omics layer is an input layer, which introduces multi-omics
features (see Eq. 3.1) from genomics (CNV), epigenomics (DNA methylation), and
transcriptomics (gene expression) data into MiNet. The multi-omics layer contains
multi-omics features of all genes, and the connections between multi-omics features
and genes are implemented by a boolean mask matrix. Note that the associations
of multi-omics features are determined with the nearest gene. Most databases often
provide genes that CNV and DNA methlayion are mapped to. At the end, every
multi-omics features are connected to only a node in the gene layer.
The gene layer represents canonical gene features computed by Eq. 3.2, where
each node indicates a gene in a biological system. Since a set of genes are involved in
biological pathways, genes in the gene layer transfer to corresponding pathway nodes
in the pathway layer. Note that the connections between genes and pathways are
given by pathway databases, so the number of nodes in the pathway layer is identical
with the number of known biological pathways. Hidden layers show hierarchical
representations of multiple pathways. A hidden node contains the interaction effect
of a set of pathways. More hidden layers may capture more complex interactions of
biological pathways.
The clinical layer is an additional input layer for clinical features (e.g., sex, age,
and tumor stage). The clinical data are introduced to the output layer as additional
features of the last hidden layer, rather than concatenating with the multi-omics layer.
The independent clinical layer prevents a few input features from dominating others
and makes the model interpretation effective in genomic level. Clinical features, such
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as age, have often been shown as significant covariates in several cancer studies. The
effects of clinical features may be suppressed by genomic features. Moreover, genomic
data and clinical data should be separated for the model interpretation.
The output layer with one node is named as a Cox layer. A linear activation
function without bias is applied to this layer to adopt Cox regression. The final
outcome of MiNet is Prognostic Index (PI) which is a linear combination of covariates,
and PI is introduced to the hazard function for the Cox proportional hazards model
as:
λ(t|x) = λ0(t) exp(PI), (3.3)
where PI is an outcome of the Cox layer in MiNet.
3.2.3 Training MiNet with Sparse Coding
MiNet minimizes the average negative log partial likelihood with L2 regular-
ization. MiNet adapts the training strategy introduced in Cox-PASNet for effective
training with high-dimensional, low-sample-size data, where small sub-networks are
randomly selected and trained with sparse coding. For the parameter initialization,
all layers are fully-connected with He’s initialization strategy [106].
The connections between the multi-omics layer and the gene layer are masked
by the given boolean mask matrix during the entire training process, similarly in the
connections between the gene layer and the pathway layer. Note that the connections
between the multi-omics layer and the pathway layer are defined by prior biological
knowledge. Sparse coding is applied to the hidden layers following the pathway layer.
We apply sparse coding (L1 regularization) individually on each layer pair,
instead of entire weight matrix. Inspired by LASSO, a soft-thresholding strategy
is applied to the connections on each layer pair. Thus, weight matrix is further
optimized on each layer pair by:
W? ← S(W, Qs), (3.4)
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where S(W, s) = sign(W)(|W|−Qs)+ is the soft-thresholding function and sign(W)
returns a sign of W. (|W| − Qs)+ returns |W| − Qs if |W| − Qs > 0, otherwise,
(|W| − Qs)+ = 0. Qs is the optimal threshold with respect to the optimal sparsity
level s. The optimal sparsity level s is estimated with the strategy proposed in Cox-
PASNet [103].
3.3 Experimental Results
In this paper, we conducted experiments with multi-omics data and clinical
data in Glioblastoma Multiforme (GBM), which is the most invasive brain tumor. We
downloaded multi-omics data including gene expressions, CNAs, and DNA methyla-
tions, and clinical data of GBM patients from The Cancer Genome Atlas (TCGA)1.
We retrieved age, survival status (living or deceased), and survival months of the
GBM patients. Age was used as a clinical feature, and both survival status and
survival months were used for response variables. The other clinical features were
not considered because of large missing values. We filtered out samples with missing
values in survival information.
For pathway-based analysis, we downloaded KEGG and Reactome pathway
databases from the Molecular Signatures Database (MSigDB) [40]. The pathway
databases consist of gene sets of well-known biological pathways, which have molecular
interactions in a cell that simultaneously lead to a certain biological process. Small
pathways with less than 25 genes were excluded to avoid large redundancy with other
pathways [43].
For the experiments, we considered genes that belong to at least one pathway.
In particular, 5,481 genes were associated with 507 pathways in the dataset. We
included CNAs and DNA methylations associated to the 5,481 genes. Missing values
in CNV and DNA methylation features were imputed by 1-Nearest Neighbor (1-NN).
Finally, we used 24,803 multi-omics features including interactions and one clinical
1https://cancergenome.nih.gov
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feature (i.e. age) from 523 samples. The dataset for benchmark models has 14,142
multi-omics features and age from 523 samples, where interactions were excluded.
Note that the benchmark methods considered much less numbers of input features
than our model.
We compared the performance of MiNet with the current cutting-edge meth-
ods: Cox regression with elastic net regularization (Cox-EN) [65], SurvivalNet [72],
and Cox-nnet [71]. Concordance index (C-index) was measured to evaluate the per-
formance of the methods. C-index is commonly used to measure the predictive per-
formance in survival analysis. We randomly split the entire data into three subsets
of training (64%), validation (16%), and test data (20%) by stratified sampling with
survival status, so that each subset preserves the same proportion of censored samples
as the entire data. Then, all features were normalized to zero mean with variance of
one. Validation and test data were normalized with the mean and variance obtained
from training data. Validation data were used to perform early stopping and grid
search for finding the optimal hyper-parameters. We repeated the experiments 20
times to show the reproducibility of the performance.
Our proposed method MiNet was implemented by PyTorch 1.0 with CUDA
10. We used ReLU for the activation function, and dropout and L2 regularization
were applied to avoid overfitting problems. Adaptive Moment Estimation (Adam)
optimizer was performed to take advantage of a fast convergence and a reduced os-
cillation. The structure of MiNet was constructed with two hidden layers following
multi-omics, gene, and pathway layers, as empirically showing better performance
than with a single hidden layer. We considered 22 and 5 nodes in the two hidden lay-
ers (H1 and H2) respectively, following the rule of thumb that the number of hidden
nodes is the square root of the number of input nodes [71]. Dropout rates were empir-
ically set as 0.7 and 0.5 for pathway layer and hidden layer, respectively. The optimal
initial learning rate (η) and L2 regularization (λ) were determined by grid search
that maximizes C-index in validation data on each experiment. All experiments were
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Table 3.1: Performance comparison of MiNet with the benchmark methods using
C-index in over 20 experiments
Model C-index (µ ± σ)
Cox-EN [65] 0.5163 ± 0.0359
SurvivalNet [72] 0.5567 ± 0.0312
Cox-nnet [71] 0.5655 ± 0.0287
MiNet (proposed) 0.6214 ± 0.0352
Table 3.2: Statistical Assessment
Wilcoxon rank-sum test
MiNet vs. Cox-EN 1e-4∗
MiNet vs. Cox-nnet 2e-4∗
MiNet vs. SurvivalNet 2e-4∗
∗ shows the statistical significance with significance level = 0.05.
performed with four NVIDIA Tesla M40 (12GB memory) Graphics Processing Units
(GPU). The source code of MiNet is publicly available in GitHub2.
Experiments of SurvivalNet [72] and Cox-nnet [71] were performed by the
Python packages published on GitHub3 4. Bayesian optimization [77] was employed
in SurvivalNet for the optimal neural network structure and hyper-parameters, such
as number of layers, number of nodes, dropout rate, L1 regularization, and L2 reg-
ularization. For Cox-nnet, grid search strategy was applied for optimal regulariza-
tion parameter (L2). Cox-EN was implemented by the package Glmnet Vignette
in Python [65]. The tunning hyperparamter λ and the elastic-net penalty term α
(α ∈ [0, 1]) were optimized by grid search. Kaplan-Meier analysis and log-rank test
were performed by using the Python package lifelines.
C-index scores obtained from Cox-EN, SurvivalNet, Cox-nnet, and MiNet over
20 experiments with GBM data are shown in Table 3.1. Our proposed method,
















Figure 3.2: Distribution of C-index with 20 experiments
ods, whereas Cox-EN, SurvivalNet, and Cox-nnet showed 0.5163 ± 0.0359, 0.5567 ±
0.0312, and 0.5655 ± 0.0287, respectively. Fig. 3.2 depicts the distribution of C-index
of the experiments. Moreover, we performed Wilcoxon rank-sum tests to assess the
statistical significance of the model improvement. As shown at Table 3.2, the out-
performance of MiNet against the other benchmarks was statistically assessed, i.e.,
p-values < 0.05.
3.4 Model Interpretation with GBM
For the model interpretation of MiNet with GBM data, we trained the model
with the entire data again using the optimal hyper-parameters that have been selected
most frequently over 20 experiments (i.e., λ = 0.02 and η = 0.005). In consequence,
the C-index of the re-trained model was 0.91, which was not overfitted to the input
data.
We first examined the six covariates, which are the input nodes to the Cox layer.
Five covariates are in the last hidden layer (H2), and one covariate (age) is from the
clinical layer. Fig. 3.3a illustrates the H2 and age node values, where the nodes are
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Figure 3.3: Graphical interpretation of the last hidden layer (H2) and the clinical
layer. (a) Heatmap of the H2 and age node values. The horizontal dashed line
separates high-risk and low-risk groups, which were separated by the median of PI.
The upper dot plot shows -log10(p-values) from the logrank test between high-risk
and low-risk groups for every single node. The right curve shows the distribution of
PI with the corresponding samples on the heatmap. (b) – (c) Kaplan-Meier plots for
the two top-ranked covariates.
Overall, the node values show high correlation with PI. Specifically, Node 2 in H2
(the first column in Fig. 3.3a) appeared as the most important covariate for predicting
survival time in MiNet with GBM data. For evaluating each covariate, we separated
the samples into two groups of high-risk and low-risk by the median of PI. Then,






















Figure 3.4: Visualization of the H2 and age nodes in MiNet using t-SNE.
in Fig. 3.3a, where all covariates were statistically significant (i.e., p-values < 0.05).
Kaplan-Meier plots are depicted in Fig. 3.3b and Fig. 3.3c with the two top-ranked
covariates, which demonstrates significantly distinct survival curves. Moreover, the
six nodes are visualized by t-SNE in Fig. 3.4, which shows a highly linear correlation
between the six covariates and the survival outcomes.
Table 3.3 shows five top-ranked pathways by MiNet, where pathway nodes are
ranked by the partial derivatives with respect to the pathway layer. It was discov-
ered that GnRH receptor is expressed in GBM [107]. Interestingly, GnRH signaling
pathway was not identified with single omics data, but significantly enriched with
multi-omics data [108]. MiNet accordingly ranked GnRH signaling pathway as a sig-
nificant factor with multi-omics data. Furthermore, the other four pathways have
been also recognized in GBM with several biological literature. The references are
listed in Table 3.3.
Two genes of NRAS and PRKACA are identified as significant in GnRH sig-
naling pathway (see Table 3.4). Then, we traced back to the multi-omics layer of
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Table 3.3: Five top-ranked pathways by MiNet
Pathways Size Ref.
GnRH signaling pathway 101 [108]
Genes involved in RNA Polymerase I, RNA
Polymerase III, and Mitochondrial Tran-
scription
122 –




Genes involved in Extracellular matrix orga-
nization
87 [111]
Table 3.4: Two top-ranked genes in GnRH signaling pathway
Genes Multi-omics Ref.
NRAS G (0.001829), G ⊗ C (0.000888), D
(0.000791),
C (0.000319), G⊗M (0.000037)
[112]
PRKACA C (0.000774), G (0.000738), G ⊗ C
(0.000698)
-
the genes. Somatic mutation of NRAS in GBM and its critical role in PI3K-AKT
pathway were reported [112]. For NRAS, the main effects of gene expression was the
most important factor, followed by the interaction effects of gene expression and CNA
and the main effect of DNA methylation. The numbers in parenthesis show partial
derivatives with respect to the input nodes, and the higher values indicate the more
important factors. For PRKACA, the main effect of CNA and gene expression were
highly ranked as the most important multi-omics factors and followed by the inter-




In this paper, we propose a gene- and pathway-based deep neural network for
multi-omics data integration, named MiNet, to predict cancer survival outcomes.
In MiNet, gene-based multi-omics features are generated by considering main and
interaction effects of multi-omics data in the multi-omics layer. The multi-omics
features produce canonical gene expression in the gene layer. The hierarchical rep-
resentations of biological processes of multi-omics, genes, and pathways are captured
in MiNet. MiNet showed the outstanding performance to predict cancer survival
outcomes with GBM patients. More importantly, MiNet provides the capability to
interpret a multi-layered biological system. A large number of biological literature
supported our biological findings from MiNet.
The multi-omics layer of MiNet is designed as a neural network module for the
integration of multi-omics data, and is compatible to the pathway-based neural net-
work, Cox-PASNet. The high flexibility and expandability of the model architecture




INTERPRETABLE AND INTEGRATIVE DEEP LEARNING FOR SURVIVAL
ANALYSIS USING HISTOPATHOLOGICAL IMAGES AND GENOMIC DATA
4.1 Introduction
Integration of histopathological images and genomic data has enhanced per-
sonalized treatments and survival predictions in cancer study, while providing an
in-depth understanding of both phenotypic patterns and genetic mechanisms of can-
cer [113, 114]. Pathological images encompass rich phenotypic information with re-
spect to tumor morphology, and high-throughput genomic data have unveiled molecu-
lar profiles of cancer [115]. Histopathology, as a clinical gold standard tool in diagnosis
and prognosis for most cancers, allows clinicians to make decisions with precision on
therapies [116]. Along with an advance of technology in microscopy, digital Whole
Slide Imaging (WSI) enables pathologists to manage histopathological tissue slides
efficiently. However, manual assessments with large-scale pathology images are highly
time-consuming and subjective even by pathologists who have varying levels of expe-
riences.
An increasing number of methods have been developed leveraging machine
learning techniques for automatic classification of cancer subtypes, identification of
metastases, and nuclei segmentation for pathological image analysis [117]. Deep learn-
ing techniques, especially convolutional neural networks, have shown tremendous po-
tential in automatic pathological image analysis. A deep max-pooling convolutional
neural network was applied for mitosis detection in breast cancer histological im-
ages [118]. A transfer learning-based deep convolutional activation features were
extracted to classify glioma grades and to segment the presence of necrosis in GBM,
where ImageNet was adopted for a pre-trained model [119]. An ensemble of CNN
was developed for improving the predictive performance of tumor grades [120]. In
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the ensemble, a CNN classified high- and low- grade glioma, and another CNN fur-
ther differentiated the grade level in low-grade glioma only. An automatic recognition
of nine important nuclear morphological characteristics in glioma pathological images
were constructed by a semi-supervised CNN and a pre-trained CNN (i.e. VGG16)
with SVM [121].
Survival analysis aims to estimate an expected survival time until a death event
occurs. More importantly, a cancer survival model investigates prognostic factors
associated to a cancer. The Cox proportional hazards model and its variants are the
most commonly applied in medical research. However, the conventional Cox model
assumes a linear relationship of covariates, which is barely applied to complex diseases
without feature selection on high-dimensional data.
Deep learning-based Cox regressions with pathological images have been stud-
ied to tackle the problems of non-linearity and multicollinearity between covariates.
Survival Convolutional Neural Networks (SCNNs) were developed to predict patient
survival outcomes by high-power fields (HPFs) from Regions Of Interests (ROIs)
that show morphological patterns with the representative tumor characteristics [122].
An Whole Slide Histopathological Images Survival Analysis framework (WSISA) was
proposed to directly learn discriminative patches based on cluster-level Deep Convo-
lutional Survival models for predicting patients’ survivals [74]. The study introduced
an aggregation strategy based on the weighted features evaluated by the performance
in each cluster.
Recently, the integration of pathological and genomic data has been explored as
a promising solution for predicting cancer survival outcomes. A lasso-regularized Cox
proportional hazards model extracted pre-defined morphological features from digital
WSIs and eigen-genes from gene coexpression data in clear cell renal cell carcinoma
and outperformed the models with either morphoological features or eigen-genes in-
dividually [113]. A multiple kernel learning-based method was introduced to extract
heterogeneous features from multiple types of genomic data and pathological images
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in breast cancer [123]. Genomic Survival convolutional neural networks (GSCNN)
integrated heterogeneous features from both pathological images and well-known ge-
nomic biomarkers for predicting patients survival with glioma [122].
Although the integrative models produced higher predictive performance than
single data models for cancer survivals, most integrative models require intensive data
preprocessing with manually annotated ROIs on pathological images and stringent
feature selection to reduce numbers of input features, e.g., using well-known genomic
biomarkers in biological literature. For instance, GSCNN integrated only two well-
known genomic biomarkers with pretrained SCNN model for reducing a number of
covariates and false negative prognostic factors [122]. Pre-defined image features of
geometry, texture, and holistic statistics were extracted from Hematoxylin and Eosin
(H&E) pathological slides, prior to integrating with gene expression data [114].
In this paper, we propose a biologically interpretable integrative deep learning
model that integrates PAthological images and GEnomic data, called PAGE-Net, not
only for improving survival predictive performance but also identifying genetic and
pathological patterns that may cause different survivals between patients. The major
methodological challenges are data heterogeneity and complexity, when integrating
unstructured mega-pixel pathological images and structured genomic data. Our main
contributions of PAGE-Net for cancer survival analysis are threefold:
• to integrate pathological images and genomic data in a biologically interpretable
deep learning model,
• to identify survival-discriminative features without manually annotated ROIs,
and
• to provide an aggregation strategy that aggregates patch-level features gener-
ated from multiple patches and produces image-level global features.
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4.2 Methods
4.2.1 The Architecture of PAGE-Net
PAGE-Net consists of pathology-specific layers, genome-specific layers, and a
demography-specific layer, each of which provides interpretability of biological mech-
anism and morphological phenotypic patterns associated to cancer survivals, as illus-
trated in Fig. 4.1. In order to tackle the integration challenge between an unstruc-
tured mega-pixel WSI and structured genomic data, we propose a novel patch-wise
texture-based convolutional neural network with a patch aggregation strategy (de-
scribed in Section 4.2.2 in detail) to extract survival-discriminative features without
manually annotated ROIs for pathology-specific layers. First, survival-discriminative
features are identified by a pre-trained deep learning model with uncensored data only.
Then, the feature scores are aggregated from multiple patches of a whole slide image,
which generates a structured vector data. For the genome-specific layers and the
demography-specific layer, we adapt our previously proposed pathway-based sparse
deep neural network, named Cox-PASNet [103]. Cox-PASNet is a cutting-edge deep
learning model that interprets biological mechanism by incorporating gene expres-
sion data, clinical data, and prior biological knowledge of pathways, while holding
outstanding predictive performance in patients’ survival with high-dimension, low-
sample size biological data. Finally, the high-level representations of pathological and
genomic data along with clinical information are introduced to a shared layer that
estimates Prognostic Index (PI) in a Cox proportional-hazards regression model.
4.2.2 Pathology-Specific Layers
In the pathology-specific layers, survival-discriminative features, which are iden-
tified in advance by a pre-trained CNN, are extracted from multiple patches of a
pathological image. Then, the features are aggregated by a two-stage pooling strat-
egy and introduced to Cox layer along with the last hidden layer of the genome-specific
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Figure 4.1: The architecture of PAGE-Net
layers and the clinical layer. We elucidate the pre-trained CNN model and the aggre-
gation strategy in the following subsections.
4.2.2.1 Patch-Wise Pre-Trained CNN
We train a CNN model to identify survival-discriminative feature maps with
patches from uncensored pathological images prior to the proposed integrative deep
learning model. Morphological patterns of pathological images are captured by the
pre-trained CNN with dilated convolutional layers. Dilated convolutional layers en-
larges field-of-view (texture) without loss of spatial information [124]. The number
of parameters does not increase with dilation, which makes model training computa-
tionally efficient. Moreover, dilated convolutional layers trade off computational time
against context assimilation [125].
The CNN model is comprised of an input layer, three pairs of dilated convo-
lutional layers (kernel size of 5 × 5, 50 feature maps, and dilation rate of 2) and a
max-pooling layer of size of 2 × 2. The sequential layers are followed by a flatten
layer and a fully connected layer. We use a linear model as the output layer, since
the model is trained with only uncensored data. Finally, the 50 neurons in the last













Figure 4.2: The architecture of the pre-trained CNN
4.2.2.2 Two-Stage Aggregation
Global survival-discriminative features for a WSI are generated by a two-stage
pooling aggregation strategy. Each patch image produces N numbers of local survival-
discriminative feature scores by the pre-trained CNN, and the scores of multiple
patches from a WSI are aggregated. The aggregated scores are introduced to the last
hidden layer in the pathology-specific layers.
We adapt a two-stage pooling approach [126] by computing 3-norm pooling
so that only a highly-ranked subset of patches are considered [119, 127]. The first
stage pooling ranks survival-discriminative features and identifies the most important
features. Then, the second stage pooling forms global survival-discriminative features
by aggregating only top-ranked patches.
The first stage pooling: Suppose that we have N survival-discriminative
feature maps identified by the pre-trained CNN on each patch image (i.e., 50 neurons
in the last max-pooling layer of the pre-trained CNN in this study). Let X denote
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N survival-discriminative feature maps, where X = [X1,X2,X3, . . . ,XN ]. The i
th
survival-discriminative feature map, Xi (1 ≤ i ≤ N), can be represented as:
Xi =

x11 x12 x13 . . . x1w






xh1 xh2 xh3 . . . xhw
 , (4.1)
where h and w are the height and the width of the feature map respectively (e.g.,
h = w = 18 in this study). Then, the flattened feature map becomes Xfi =
[x11, x12, x13, . . . , xhw]. After sorting the flattened feature map in the descending or-
der, we consider top K1 features as significant survival-discriminative feature map
components, which is X̃
f











where fi is an aggregated score for the i
th feature map on a patch.
The second stage pooling: Suppose that M numbers of patches are available
on a WSI. The aggregated feature maps of all patches after the first stage pooling
can be represented as:
F =

f11 f12 f13 . . . f1N






fM1 fM2 fM3 . . . fMN
 , (4.3)
where fij is the j
th feature map of the ith patch on a WSI, which is computed by Eq.
(4.2). For each column of F (i.e. feature maps over M patches), we sort column-
wise values in the descending order. The top K2 number of values (i.e. important
patches) in each column are truncated, i.e., f̃ij, 1 ≤ i ≤ K2. Then, another 3-norm
pooling is performed on each column of the truncated F. An aggregated score of
top K2 discriminative patches is obtained for a feature map. Therefore, a vector
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of N aggregated survival-discriminative features represents a pathological WSI for a
patient. In this study, we used N = 50, M = 1000, K1 = 65, and K2 = 100.
4.2.3 Genome- and demography-specific layers
The genome- and demography-specific layers are adapted from the pathway-
based sparse deep neural network, Cox-PASNet [103]. The genome-specific layers
include a gene layer, a pathway layer, and two hidden layers (H1 and H2). The gene
layer is an input layer for gene expression data, where each node indicates a gene.
The pathway layer embeds a prior biological knowledge using well-known biologi-
cal pathway databases (e.g., KEGG) for biological interpretation. The connection
between the gene layer and the pathway layer are sparsely established by given bio-
logical pathway databases where the relationships between genes and pathways are
available. Hence, each pathway node explicitly represents a biological pathway. The
following two hidden layers capture nonlinear and hierarchical relationships between
pathways. Clinical data of a patient are directly introduced to the demography-
specific layer and combined with genomic features from gene expressions and aggre-
gated survival-discriminative features from a pathological image in the last hidden
layer of the integrative model.
Overfitting is a critical issue to avoid when training a deep learning model with
high-dimension, low-sample-size data. In order to prevent the overfitting problem,
PAGE-Net applies the training technique that Cox-PASNet proposed [103]. Instead
of training the whole network, small networks are randomly selected, and sparse
coding was applied to make connection sparse for model interpretation. The training
is repeated until it converges. Errors with the validation data was also traced for
early stopping and preventing overfitting.
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4.3 Experimental Results
We examined pathological images, gene expression data, and clinical data of
Glioblastoma Multiforme (GBM) patients to assess our proposed model. The data
were downloaded from The Cancer Imaging Archive (TCIA) 1 and The Cancer Genome
Atlas (TCGA) that provide pathological images and genomics data from an identical
set of patients. We considered only GBM patients’ data where both gene expression
and pathological image are available. We also filtered out the data without survival
information. We included age only as a clinical feature for the demography-specific
layer, i.e. clinical layer, since a large amount of missing values are shown in other
clinical features.
KEGG and Reactome pathway databases, taken from the Molecular Signatures
Database (MSigDB) [40, 41, 42], were used for biological pathways in the model, as a
prior biological knowledge. Biological pathways that have either less than fifteen genes
or over 300 genes were excluded [43]. Furthermore, only genes that belong to at least
one pathway were considered as inputs to the model. Finally, we considered 5,404
genes of 447 GBM patients and 659 pathways were examined. For the pathological
WSI, we considered WSIs of “top” frozen tissue sections with the 20X magnification.
In the pre-training phase, 1,000 patches of size 256 × 256 were randomly sampled
from the uncensored data for training the pre-train CNN. Note that only uncensored
training and validation data were used for the pre-trained CNN on each experiment.
In the integration phase, we sampled other 1,000 patches from a WSI for training and
testing.
We compared the predictive performance of PAGE-Net with Cox-PASNet and
Cox regression with elastic net regularization (Cox-EN) [65]. Cox-PASNet was ap-
plied to gene expressions and age, whereas aggregated survival-discriminative image
features were trained by Cox-EN. Concordance index (C-index) with counted tied
prediction pairs was measured to scale the performance of the models. The samples
1https://www.cancerimagingarchive.net/
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were randomly split into training (80%), validation (10%), and test (10%) sets, by
preserving the proportion between censored and uncensored statuses. The features
in the training set were normalized to mean of zero and standard deviation of one.
The validation and the test sets were normalized by the mean and standard devia-
tion from the training set. We repeated the experiments twenty times to show the
reproducibility of the performance.
PAGE-Net was implemented by PyTorch 1.0 with CUDA 10.0.130 and Keras
2.2.4 with TensorFlow 1.13.1 as backend. The model was optimized with the dilated
kernel size of 5×5, dilated rate r of 2, and the max pooling size is 2×2. A dropout
rate of 0.3 was applied for each dilated conventional layers and flatten layer. We
used Adaptive Moment Estimation (Adam) optimizer and ReLU activation function.
Mean squared error (MSE) was computed as the loss. A grid search was performed
on each experiment to optimize a learning rate and a mini-batch size using validation
data with a learning rate decay of 0.7 for every 5 epochs. An early stopping upon
validation loss was applied.
In the integration phrase, Tanh function was used as the activation function
between layers. We set 100, 30, and 30 nodes for H1, H2, and the pathology hidden
layer, respectively. Dropout rates were empirically set as 0.7, 0.5, and 0.3 for the
pathway layer, H1, and the global survival-discriminative feature layer, respectively.
The optimal learning rate and L2 regularization (λ) were automatically determined
by grid search so as to maximize C-index with the validation data on each experiment.
All experiments were performed with two NVIDIA Tesla M40 (8 cores, 12GB memory
per each core) Graphics Processing Units (GPUs). The source code of PAGE-Net is
accessible online via GitHub (https://github.com/DataX-JieHao/PAGE-Net). For
the benchmark methods, Cox-PASNet was performed in the proposed manner in the
paper. Cox-EN was implemented by the Python version of Glmnet Vignette [65]. 200
λs were considered for optimization. The regularization term α between zero and one











Figure 4.3: Performance comparison over 20 experiments with GBM in C-index
The experimental results with GBM data are shown in Fig. 4.3. Our proposed
model, PAGE-Net, achieved the highest C-index of 0.702 ± 0.0294 (mean ± std) com-
paring to Cox-PASNet (with gene expressions and age) showing C-index of 0.6401 ±
0.00399, and Cox-EN (with aggregated image features) showing the lowest C-index
of 0.5093 ± 0.0460. The highest C-index of PAGE-Net shows the increased power
of the integrative model with pathological data and genomic data. Interestingly, a
pathological WSI itself contributes little to the predictive performance. However,
the experimental results show that the pathological WSI boosted the performance
of survival analysis with genomic data in the proposed integrative model. The per-
formances were assessed by Wilconxon rank-sum test, and PAGE-Net statistically
outperformed Cox-EN with pathological images only and Cox-PASNet with genomic






























































Figure 4.4: Survival-discriminative feature maps on the patches of three patients in
various survivals
4.4 Model Interpretation
For the model interpretation of PAGE-Net, we re-trained the proposed models
using the entire data and the optimal hyper-parameters that were most commonly
used over the 20 experiments. We performed the analysis for biological interpretation
with the pathology- and genome-specific layers. For the pathology-specific layers,
we assessed pathological and morphological patterns of the survival-discriminative
feature maps with a pathologist. For the genome-specific layers, we conducted the
pathway-based interpretation by ranking the nodes with partial derivatives, as Cox-
PASNet conducted [103].
Figure 4.4 exhibits pathological top-ranked patch images of three patients in
a short (first row; TCGA-06-402-01 ; survival month = 0.53), median (second row;
TCGA-26-1439-01 ; survival month = 13.85), and long-term (third row; TCGA-08-
0344-01 ; survival month = 115.3) survivals and the survival-discriminative feature
maps captured by the pre-trained CNN on the patches. The survival-discriminative
feature map scores (higher than the median) are colored in red in the figures. Inter-
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estingly, the survival-discriminative feature maps capture most nucleus and nuclear
debris of interest on the patches. In GBM where boundaries between nuclei are not
clearly shown, a distance between nuclei and a shape of nucleus are critical checkpoints
on tissue readings. The feature maps show that the morphological patterns of pathol-
ogist’s interest are also recognized by the proposed model. Moreover, nuclear debris
implies necrosis of nucleus, and the relationship between nuclear debris and survival
prognosis is known. The top-ranked patches were measured scores of nuclear pleomor-
phism (NP), cytoplasmic degeneration (CD), and brown pigment (BP) using three
tiered scoring by a pathologist. The scores of NP, CD, and BP on TCGA-06-402-01
were +3, +3, and +3, whereas the scores of TCGA-26-1439-01 and TCGA-08-0344-
01 were +1, 0, and 0. The patch of the patient, TCGA-06-402-01, shows more severe
scores on NP, CD, and BP than other two patients. It shows that PAGE-Net can
also identify regions (patches) associated to patients’ survival on a WSI.
Ten top-ranked pathways and genes in GBM are ranked with the genome-
specific layers in PAGE-Net. The pathways and genes are listed in Table 4.1 and
Table 4.2. Neuroactive ligand-receptor interaction pathway, ranked top one by PAGE-
Net, is well known as one of the most associated pathways to GBM [80]. Survival
models by both univariate and multivariate Cox regression analysis for the nine long
noncoding RNAs (lncRNAs) in GBM identified neuroactive ligand-receptor interac-
tion pathway as the most related pathway [128]. Axon guidance pathway harbored
the top-ranked CNVs with respect to GBM [83]. The downregulation of endocyto-
sis pathway was likely to be a common trait in glioma tumors [129]. For instance,
the down-regulated differentially expressed genes (DEGs) assoiciated with the glioma
gene expression profile GSE4290 were enriched in endocytosis pathway [130]. Colla-
gen formation pathway enriched for the candidate genes identified by weighted gene
co-expression network analysis with RNA sequencings of GBM patients from the Chi-
nese Glioma Genome Atlas database [131]. 18 cytokines, which differentiated normal

















































































































































































































































































































Table 4.2: Ten top-ranked genes in GBM by PAGE-Net











tion and JAK-STAT pathways [132]. Furthermore, overexpressed ADORA2A is one of
the evidences for high-grade gliomas by the World Health Organization (WTO) [135].
HTR7, enriched in neuroactive ligandreceptor interaction, was reported to contribute
the diffuse intrinsic pontine glioma development and progression [92]. MET, well-
known as an oncogene, has been revealed as a functional marker in Glioblastoma
stem cells since it benefits glioma invasiveness and self-reconstruction [136].
Figure 4.5 shows hierarchical biological mechanisms on both pathological im-
ages and genomic data in PAGE-Net. In the pathology-specific layers, morphologi-
cal patterns, which are associated to patients’ survivals, are scored by the survival-
discriminative features, and the global features are introduced to the model. The
survival-discriminative feature maps substantially capture the nucleus and nuclear
debris of interest on a WSI. In the genome-specific layers, activated genes including
ADORA2A and ADORA2B trigger the neuroactive ligand-receptor interaction path-
way, and the pathway contributes patient’s survivals in a non-linear manner with
other pathways in the hidden layers. The Kaplan-Meier plots of the pathway and


















































Figure 4.5: Overview of the model interpretation
separated by the median of the node values. The Node 13 values can be considered
as a potential prognostic factor that can predict patient’s survival.
4.5 Conclusion
In this paper, we propose an integrative deep learning model (PAGE-Net) that
captures both morphological patterns on pathological WSIs and pathway-based ge-
netic mechanisms of a complex human cancer, while predicting cancer survival out-
comes with pathological images and genomic data. PAGE-Net produced the out-
standing predictive performance and showed promising potential to identify genetic
and pathological prognostic factors simultaneously associated with patients survival.
The survival-discriminative features identified by the pre-trained CNN was asssessed
by a pathologist that the features can identify nucleus and nuclear debris, which may
be related to patient’ survivals. The integrative deep learning model, PAGE-Net, also
shows that the data integration of pathological images and genomic data is essential
for enhancing patient’s survival rather than analyses with a single data type.
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